[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fujkC5NcbQtHQpm2lQX8Irp7qE11Z9U4ZfH8NK70RwMg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":82,"rows":89},"Mario Negri Institute for Pharmacological Research",[4],155,false,44,24,1647768,13,70,[14,17,20,22,25,27,29,31],{"name":15,"count":16},"Membranous Nephropathy",6,{"name":18,"count":19},"Type 2 Diabetes",5,{"name":21,"count":19},"Autosomal Dominant Polycystic Kidney Disease (ADPKD)",{"name":23,"count":24},"Nephrotic Syndrome",4,{"name":26,"count":24},"Evaluation",{"name":28,"count":24},"Kidney Transplant",{"name":30,"count":24},"Emergency Departments",{"name":32,"count":24},"Hypertension",[34,39,44,49,54,59,64,69,74,79],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT06193616","Outcome of ADPKD With Octreotide LAR","2024-12-31","Octreotide",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06374095","1 vs 7 RATG Infusions in Renal Transplantation","2025-09","RATG",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05050214","Obinutuzumab in Primary MN","2026-02","Obinutuzumab",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT05482945","CardioPulmonary Resuscitation With Argon (CPAr) Trial","2026-03-31","Noble gas Argon",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06858280","Patiromer and Diet\u002FhrQoL in Chronic Dialysis","2026-07","Patiromer 8400 MG [Veltassa]",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06121401","First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients","2027-03-15","Olaparib",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT06126315","Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS","2027-04","Acetyl-l-carnitine",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06680050","Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +\u002F- Oligometastases After PACIFIC Regimen","2028-06","Durvalumab",{"nctId":75,"briefTitle":76,"date":77,"intervention":78},"NCT07416942","Omics of Rituximab-resistance","2029-03","Multi-omics Analysis",{"nctId":80,"briefTitle":81,"date":77,"intervention":48},"NCT07233330","Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome",[83,84,85,86,87,88],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[90,130,148,172,194,221,268,296,319,337,359,377,396,417,457,475,493,511,529,547,565,583,601,619,637,655,673,691,709,727,758,776,794,812,830,848,876,901,927,945,973,991,1009,1070,1104,1126,1148,1190,1223,1260,1282,1317,1339,1361,1384,1408,1426,1450,1476,1500,1518,1543,1570,1588,1614,1639,1657,1682,1707,1731,1754,1772,1808,1840,1875,1901,1925,1943,1961,1986,2004,2022,2044,2068,2086,2112,2136,2154,2177,2195,2220,2245,2263,2281,2299,2324,2350,2375,2393,2418,2436,2460,2478,2496,2514,2540,2558,2581,2603,2629,2647,2672,2696,2719,2743,2767,2792,2835,2875,2897,2919,2941,2963,2981,2999,3017,3042,3067],{"intervention":63,"totalTrials":91,"cells":92},2,{"EARLY_PHASE1":93,"PHASE1":96,"PHASE2":98,"PHASE3":113,"PHASE4":115,"NA":128},{"trials":94,"activeCount":95},[],0,{"trials":97,"activeCount":95},[],{"trials":99,"activeCount":95},[100],{"nctId":101,"briefTitle":102,"status":103,"phases":104,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":110},"NCT03314740","Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib","COMPLETED",[85],"2021-04-01","2017-06-12",123,[109],"Ovarian Neoplasms",[111,112,63],"Paclitaxel","Cediranib",{"trials":114,"activeCount":95},[],{"trials":116,"activeCount":127,"soonestReadout":62},[117],{"nctId":60,"briefTitle":61,"status":118,"phases":119,"primaryCompletion":62,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":125},"ACTIVE_NOT_RECRUITING",[87],"2027-09-15","2023-09-15",190,[124],"Carcinoma, Ovarian Epithelial",[63,126],"Bevacizumab",1,{"trials":129,"activeCount":95},[],{"intervention":126,"totalTrials":127,"cells":131},{"EARLY_PHASE1":132,"PHASE1":134,"PHASE2":136,"PHASE3":138,"PHASE4":140,"NA":146},{"trials":133,"activeCount":95},[],{"trials":135,"activeCount":95},[],{"trials":137,"activeCount":95},[],{"trials":139,"activeCount":95},[],{"trials":141,"activeCount":127,"soonestReadout":62},[142],{"nctId":60,"briefTitle":61,"status":118,"phases":143,"primaryCompletion":62,"completion":120,"start":121,"enrollment":122,"conditions":144,"interventions":145},[87],[124],[63,126],{"trials":147,"activeCount":95},[],{"intervention":58,"totalTrials":127,"cells":149},{"EARLY_PHASE1":150,"PHASE1":152,"PHASE2":154,"PHASE3":156,"PHASE4":168,"NA":170},{"trials":151,"activeCount":95},[],{"trials":153,"activeCount":95},[],{"trials":155,"activeCount":95},[],{"trials":157,"activeCount":127,"soonestReadout":57},[158],{"nctId":55,"briefTitle":56,"status":159,"phases":160,"primaryCompletion":57,"completion":57,"start":161,"enrollment":162,"conditions":163,"interventions":167},"RECRUITING",[86],"2025-07-08",40,[164,165,166],"Hyperkalaemia","Chronic Kidney Disease Stage 3 and 4","Dietary Intervention",[58],{"trials":169,"activeCount":95},[],{"trials":171,"activeCount":95},[],{"intervention":68,"totalTrials":127,"cells":173},{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":178,"PHASE3":180,"PHASE4":190,"NA":192},{"trials":175,"activeCount":95},[],{"trials":177,"activeCount":95},[],{"trials":179,"activeCount":95},[],{"trials":181,"activeCount":127,"soonestReadout":67},[182],{"nctId":65,"briefTitle":66,"status":159,"phases":183,"primaryCompletion":67,"completion":184,"start":185,"enrollment":186,"conditions":187,"interventions":189},[85,86],"2027-09","2025-03-26",246,[188],"Amyotrophic Lateral Sclerosis",[68],{"trials":191,"activeCount":95},[],{"trials":193,"activeCount":95},[],{"intervention":48,"totalTrials":91,"cells":195},{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":215,"PHASE4":217,"NA":219},{"trials":197,"activeCount":95},[],{"trials":199,"activeCount":95},[],{"trials":201,"activeCount":91,"soonestReadout":47},[202,208],{"nctId":45,"briefTitle":46,"status":118,"phases":203,"primaryCompletion":47,"completion":47,"start":204,"enrollment":205,"conditions":206,"interventions":207},[85],"2022-02-18",20,[15],[48],{"nctId":80,"briefTitle":81,"status":209,"phases":210,"primaryCompletion":77,"completion":77,"start":47,"enrollment":211,"conditions":212,"interventions":214},"NOT_YET_RECRUITING",[85],10,[213],"Nephrotic Syndrome，Idiopathic",[48],{"trials":216,"activeCount":95},[],{"trials":218,"activeCount":95},[],{"trials":220,"activeCount":95},[],{"intervention":73,"totalTrials":222,"cells":223},3,{"EARLY_PHASE1":224,"PHASE1":226,"PHASE2":228,"PHASE3":262,"PHASE4":264,"NA":266},{"trials":225,"activeCount":95},[],{"trials":227,"activeCount":95},[],{"trials":229,"activeCount":127,"soonestReadout":72},[230,240,249],{"nctId":231,"briefTitle":232,"status":103,"phases":233,"primaryCompletion":234,"completion":234,"start":235,"enrollment":236,"conditions":237,"interventions":239},"NCT04115111","Diadem to Investigate the Activity and Safety of Durvalumab",[85],"2019-05-16","2018-10-17",57,[238],"Pleura Mesothelioma",[73],{"nctId":70,"briefTitle":71,"status":159,"phases":241,"primaryCompletion":72,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":247},[85],"2029-01","2025-08-07",21,[246],"Non Small Cell Lung Cancer NSCLC",[73,248],"Ceralasertib",{"nctId":250,"briefTitle":251,"status":252,"phases":253,"primaryCompletion":254,"completion":254,"start":255,"enrollment":211,"conditions":256,"interventions":258},"NCT04765709","Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC","TERMINATED",[85],"2025-01-30","2021-09-24",[257],"Non-small Cell Lung Cancer Stage III",[259,260,261],"durvalumab plus platinum-based chemotherapy","Durvalumab plus radiotherapy","durvalumab",{"trials":263,"activeCount":95},[],{"trials":265,"activeCount":95},[],{"trials":267,"activeCount":95},[],{"intervention":269,"totalTrials":127,"cells":270},"Abemaciclib",{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":290,"PHASE4":292,"NA":294},{"trials":272,"activeCount":95},[],{"trials":274,"activeCount":95},[],{"trials":276,"activeCount":127,"soonestReadout":281},[277],{"nctId":278,"briefTitle":279,"status":209,"phases":280,"primaryCompletion":281,"completion":281,"start":282,"enrollment":283,"conditions":284,"interventions":289},"NCT07428018","Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+\u002FHER2- Early Breast Cancer Using Oncotype DX and Abemaciclib",[85],"2029-04-30","2026-04-30",150,[285,286,287,288],"Breast Cancer","HER2 + Breast Cancer","HR Positive","Neoadjuvant Therapy",[269],{"trials":291,"activeCount":95},[],{"trials":293,"activeCount":95},[],{"trials":295,"activeCount":95},[],{"intervention":53,"totalTrials":127,"cells":297},{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":313,"PHASE4":315,"NA":317},{"trials":299,"activeCount":95},[],{"trials":301,"activeCount":95},[],{"trials":303,"activeCount":127,"soonestReadout":52},[304],{"nctId":50,"briefTitle":51,"status":159,"phases":305,"primaryCompletion":52,"completion":306,"start":307,"enrollment":308,"conditions":309,"interventions":312},[85],"2026-06-30","2022-05-30",120,[310,311],"Cardiac Arrest, Out-Of-Hospital","Cardiac Arrest With Successful Resuscitation",[53],{"trials":314,"activeCount":95},[],{"trials":316,"activeCount":95},[],{"trials":318,"activeCount":95},[],{"intervention":248,"totalTrials":127,"cells":320},{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":331,"PHASE4":333,"NA":335},{"trials":322,"activeCount":95},[],{"trials":324,"activeCount":95},[],{"trials":326,"activeCount":127,"soonestReadout":72},[327],{"nctId":70,"briefTitle":71,"status":159,"phases":328,"primaryCompletion":72,"completion":242,"start":243,"enrollment":244,"conditions":329,"interventions":330},[85],[246],[73,248],{"trials":332,"activeCount":95},[],{"trials":334,"activeCount":95},[],{"trials":336,"activeCount":95},[],{"intervention":43,"totalTrials":127,"cells":338},{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":345,"PHASE4":347,"NA":349},{"trials":340,"activeCount":95},[],{"trials":342,"activeCount":95},[],{"trials":344,"activeCount":95},[],{"trials":346,"activeCount":95},[],{"trials":348,"activeCount":95},[],{"trials":350,"activeCount":127,"soonestReadout":42},[351],{"nctId":40,"briefTitle":41,"status":118,"phases":352,"primaryCompletion":42,"completion":42,"start":353,"enrollment":354,"conditions":355,"interventions":357},[],"2024-07-30",75,[356],"Kidney Replacement",[43,358],"Basiliximab",{"intervention":358,"totalTrials":127,"cells":360},{"EARLY_PHASE1":361,"PHASE1":363,"PHASE2":365,"PHASE3":367,"PHASE4":369,"NA":371},{"trials":362,"activeCount":95},[],{"trials":364,"activeCount":95},[],{"trials":366,"activeCount":95},[],{"trials":368,"activeCount":95},[],{"trials":370,"activeCount":95},[],{"trials":372,"activeCount":127,"soonestReadout":42},[373],{"nctId":40,"briefTitle":41,"status":118,"phases":374,"primaryCompletion":42,"completion":42,"start":353,"enrollment":354,"conditions":375,"interventions":376},[],[356],[43,358],{"intervention":78,"totalTrials":127,"cells":378},{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":385,"PHASE4":387,"NA":389},{"trials":380,"activeCount":95},[],{"trials":382,"activeCount":95},[],{"trials":384,"activeCount":95},[],{"trials":386,"activeCount":95},[],{"trials":388,"activeCount":95},[],{"trials":390,"activeCount":127,"soonestReadout":77},[391],{"nctId":75,"briefTitle":76,"status":209,"phases":392,"primaryCompletion":77,"completion":77,"start":393,"enrollment":308,"conditions":394,"interventions":395},[],"2026-04",[15],[78],{"intervention":38,"totalTrials":127,"cells":397},{"EARLY_PHASE1":398,"PHASE1":400,"PHASE2":402,"PHASE3":404,"PHASE4":406,"NA":408},{"trials":399,"activeCount":95},[],{"trials":401,"activeCount":95},[],{"trials":403,"activeCount":95},[],{"trials":405,"activeCount":95},[],{"trials":407,"activeCount":95},[],{"trials":409,"activeCount":127,"soonestReadout":37},[410],{"nctId":35,"briefTitle":36,"status":118,"phases":411,"primaryCompletion":37,"completion":412,"start":413,"enrollment":12,"conditions":414,"interventions":416},[],"2025-12","2024-02-12",[415],"Autosomal Dominant Polycystic Kidney",[38],{"intervention":418,"totalTrials":127,"cells":419},"Low dose carbamazepine",{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":426,"PHASE4":428,"NA":455},{"trials":421,"activeCount":95},[],{"trials":423,"activeCount":95},[],{"trials":425,"activeCount":95},[],{"trials":427,"activeCount":95},[],{"trials":429,"activeCount":95},[430],{"nctId":431,"briefTitle":432,"status":103,"phases":433,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":437,"interventions":439},"NCT03689114","Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW)",[87],"2024-06-30","2021-05-10",58,[438],"Epilepsies, Partial",[418,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454],"Standard dose carbamazepine","Low dose levetiracetam","Standard dose levetiracetam","Low dose valproate","Standard dose valproate","Low dose zonisamide","Standard dose zonisamide","Low dose oxcarbazepine","Standard dose oxcarbazepine","Low dose topiramate","Standard dose topiramate","Low dose lamotrigine","Standard dose lamotrigine","Low dose gabapentin","Standard dose gabapentin",{"trials":456,"activeCount":95},[],{"intervention":440,"totalTrials":127,"cells":458},{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":465,"PHASE4":467,"NA":473},{"trials":460,"activeCount":95},[],{"trials":462,"activeCount":95},[],{"trials":464,"activeCount":95},[],{"trials":466,"activeCount":95},[],{"trials":468,"activeCount":95},[469],{"nctId":431,"briefTitle":432,"status":103,"phases":470,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":471,"interventions":472},[87],[438],[418,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454],{"trials":474,"activeCount":95},[],{"intervention":441,"totalTrials":127,"cells":476},{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":483,"PHASE4":485,"NA":491},{"trials":478,"activeCount":95},[],{"trials":480,"activeCount":95},[],{"trials":482,"activeCount":95},[],{"trials":484,"activeCount":95},[],{"trials":486,"activeCount":95},[487],{"nctId":431,"briefTitle":432,"status":103,"phases":488,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":489,"interventions":490},[87],[438],[418,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454],{"trials":492,"activeCount":95},[],{"intervention":442,"totalTrials":127,"cells":494},{"EARLY_PHASE1":495,"PHASE1":497,"PHASE2":499,"PHASE3":501,"PHASE4":503,"NA":509},{"trials":496,"activeCount":95},[],{"trials":498,"activeCount":95},[],{"trials":500,"activeCount":95},[],{"trials":502,"activeCount":95},[],{"trials":504,"activeCount":95},[505],{"nctId":431,"briefTitle":432,"status":103,"phases":506,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":507,"interventions":508},[87],[438],[418,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454],{"trials":510,"activeCount":95},[],{"intervention":443,"totalTrials":127,"cells":512},{"EARLY_PHASE1":513,"PHASE1":515,"PHASE2":517,"PHASE3":519,"PHASE4":521,"NA":527},{"trials":514,"activeCount":95},[],{"trials":516,"activeCount":95},[],{"trials":518,"activeCount":95},[],{"trials":520,"activeCount":95},[],{"trials":522,"activeCount":95},[523],{"nctId":431,"briefTitle":432,"status":103,"phases":524,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":525,"interventions":526},[87],[438],[418,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454],{"trials":528,"activeCount":95},[],{"intervention":444,"totalTrials":127,"cells":530},{"EARLY_PHASE1":531,"PHASE1":533,"PHASE2":535,"PHASE3":537,"PHASE4":539,"NA":545},{"trials":532,"activeCount":95},[],{"trials":534,"activeCount":95},[],{"trials":536,"activeCount":95},[],{"trials":538,"activeCount":95},[],{"trials":540,"activeCount":95},[541],{"nctId":431,"briefTitle":432,"status":103,"phases":542,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":543,"interventions":544},[87],[438],[418,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454],{"trials":546,"activeCount":95},[],{"intervention":445,"totalTrials":127,"cells":548},{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":555,"PHASE4":557,"NA":563},{"trials":550,"activeCount":95},[],{"trials":552,"activeCount":95},[],{"trials":554,"activeCount":95},[],{"trials":556,"activeCount":95},[],{"trials":558,"activeCount":95},[559],{"nctId":431,"briefTitle":432,"status":103,"phases":560,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":561,"interventions":562},[87],[438],[418,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454],{"trials":564,"activeCount":95},[],{"intervention":446,"totalTrials":127,"cells":566},{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":571,"PHASE3":573,"PHASE4":575,"NA":581},{"trials":568,"activeCount":95},[],{"trials":570,"activeCount":95},[],{"trials":572,"activeCount":95},[],{"trials":574,"activeCount":95},[],{"trials":576,"activeCount":95},[577],{"nctId":431,"briefTitle":432,"status":103,"phases":578,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":579,"interventions":580},[87],[438],[418,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454],{"trials":582,"activeCount":95},[],{"intervention":447,"totalTrials":127,"cells":584},{"EARLY_PHASE1":585,"PHASE1":587,"PHASE2":589,"PHASE3":591,"PHASE4":593,"NA":599},{"trials":586,"activeCount":95},[],{"trials":588,"activeCount":95},[],{"trials":590,"activeCount":95},[],{"trials":592,"activeCount":95},[],{"trials":594,"activeCount":95},[595],{"nctId":431,"briefTitle":432,"status":103,"phases":596,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":597,"interventions":598},[87],[438],[418,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454],{"trials":600,"activeCount":95},[],{"intervention":448,"totalTrials":127,"cells":602},{"EARLY_PHASE1":603,"PHASE1":605,"PHASE2":607,"PHASE3":609,"PHASE4":611,"NA":617},{"trials":604,"activeCount":95},[],{"trials":606,"activeCount":95},[],{"trials":608,"activeCount":95},[],{"trials":610,"activeCount":95},[],{"trials":612,"activeCount":95},[613],{"nctId":431,"briefTitle":432,"status":103,"phases":614,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":615,"interventions":616},[87],[438],[418,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454],{"trials":618,"activeCount":95},[],{"intervention":449,"totalTrials":127,"cells":620},{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":625,"PHASE3":627,"PHASE4":629,"NA":635},{"trials":622,"activeCount":95},[],{"trials":624,"activeCount":95},[],{"trials":626,"activeCount":95},[],{"trials":628,"activeCount":95},[],{"trials":630,"activeCount":95},[631],{"nctId":431,"briefTitle":432,"status":103,"phases":632,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":633,"interventions":634},[87],[438],[418,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454],{"trials":636,"activeCount":95},[],{"intervention":450,"totalTrials":127,"cells":638},{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":643,"PHASE3":645,"PHASE4":647,"NA":653},{"trials":640,"activeCount":95},[],{"trials":642,"activeCount":95},[],{"trials":644,"activeCount":95},[],{"trials":646,"activeCount":95},[],{"trials":648,"activeCount":95},[649],{"nctId":431,"briefTitle":432,"status":103,"phases":650,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":651,"interventions":652},[87],[438],[418,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454],{"trials":654,"activeCount":95},[],{"intervention":451,"totalTrials":127,"cells":656},{"EARLY_PHASE1":657,"PHASE1":659,"PHASE2":661,"PHASE3":663,"PHASE4":665,"NA":671},{"trials":658,"activeCount":95},[],{"trials":660,"activeCount":95},[],{"trials":662,"activeCount":95},[],{"trials":664,"activeCount":95},[],{"trials":666,"activeCount":95},[667],{"nctId":431,"briefTitle":432,"status":103,"phases":668,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":669,"interventions":670},[87],[438],[418,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454],{"trials":672,"activeCount":95},[],{"intervention":452,"totalTrials":127,"cells":674},{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":679,"PHASE3":681,"PHASE4":683,"NA":689},{"trials":676,"activeCount":95},[],{"trials":678,"activeCount":95},[],{"trials":680,"activeCount":95},[],{"trials":682,"activeCount":95},[],{"trials":684,"activeCount":95},[685],{"nctId":431,"briefTitle":432,"status":103,"phases":686,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":687,"interventions":688},[87],[438],[418,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454],{"trials":690,"activeCount":95},[],{"intervention":453,"totalTrials":127,"cells":692},{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":697,"PHASE3":699,"PHASE4":701,"NA":707},{"trials":694,"activeCount":95},[],{"trials":696,"activeCount":95},[],{"trials":698,"activeCount":95},[],{"trials":700,"activeCount":95},[],{"trials":702,"activeCount":95},[703],{"nctId":431,"briefTitle":432,"status":103,"phases":704,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":705,"interventions":706},[87],[438],[418,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454],{"trials":708,"activeCount":95},[],{"intervention":454,"totalTrials":127,"cells":710},{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":715,"PHASE3":717,"PHASE4":719,"NA":725},{"trials":712,"activeCount":95},[],{"trials":714,"activeCount":95},[],{"trials":716,"activeCount":95},[],{"trials":718,"activeCount":95},[],{"trials":720,"activeCount":95},[721],{"nctId":431,"briefTitle":432,"status":103,"phases":722,"primaryCompletion":434,"completion":434,"start":435,"enrollment":436,"conditions":723,"interventions":724},[87],[438],[418,440,441,442,443,444,445,446,447,448,449,450,451,452,453,454],{"trials":726,"activeCount":95},[],{"intervention":728,"totalTrials":127,"cells":729},"Tocilizumab",{"EARLY_PHASE1":730,"PHASE1":732,"PHASE2":734,"PHASE3":736,"PHASE4":738,"NA":756},{"trials":731,"activeCount":95},[],{"trials":733,"activeCount":95},[],{"trials":735,"activeCount":95},[],{"trials":737,"activeCount":95},[],{"trials":739,"activeCount":95},[740],{"nctId":741,"briefTitle":742,"status":252,"phases":743,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":748,"interventions":750},"NCT03100253","Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation",[87],"2021-12-01","2021-12-31","2018-03-01",208,[749],"Rheumatoid Arthritis",[728,751,752,753,754,755],"Etanercept","Infliximab","Adalimumab","Golimumab","Certolizumab Pegol",{"trials":757,"activeCount":95},[],{"intervention":751,"totalTrials":127,"cells":759},{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":764,"PHASE3":766,"PHASE4":768,"NA":774},{"trials":761,"activeCount":95},[],{"trials":763,"activeCount":95},[],{"trials":765,"activeCount":95},[],{"trials":767,"activeCount":95},[],{"trials":769,"activeCount":95},[770],{"nctId":741,"briefTitle":742,"status":252,"phases":771,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":772,"interventions":773},[87],[749],[728,751,752,753,754,755],{"trials":775,"activeCount":95},[],{"intervention":752,"totalTrials":127,"cells":777},{"EARLY_PHASE1":778,"PHASE1":780,"PHASE2":782,"PHASE3":784,"PHASE4":786,"NA":792},{"trials":779,"activeCount":95},[],{"trials":781,"activeCount":95},[],{"trials":783,"activeCount":95},[],{"trials":785,"activeCount":95},[],{"trials":787,"activeCount":95},[788],{"nctId":741,"briefTitle":742,"status":252,"phases":789,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":790,"interventions":791},[87],[749],[728,751,752,753,754,755],{"trials":793,"activeCount":95},[],{"intervention":753,"totalTrials":127,"cells":795},{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":802,"PHASE4":804,"NA":810},{"trials":797,"activeCount":95},[],{"trials":799,"activeCount":95},[],{"trials":801,"activeCount":95},[],{"trials":803,"activeCount":95},[],{"trials":805,"activeCount":95},[806],{"nctId":741,"briefTitle":742,"status":252,"phases":807,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":808,"interventions":809},[87],[749],[728,751,752,753,754,755],{"trials":811,"activeCount":95},[],{"intervention":754,"totalTrials":127,"cells":813},{"EARLY_PHASE1":814,"PHASE1":816,"PHASE2":818,"PHASE3":820,"PHASE4":822,"NA":828},{"trials":815,"activeCount":95},[],{"trials":817,"activeCount":95},[],{"trials":819,"activeCount":95},[],{"trials":821,"activeCount":95},[],{"trials":823,"activeCount":95},[824],{"nctId":741,"briefTitle":742,"status":252,"phases":825,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":826,"interventions":827},[87],[749],[728,751,752,753,754,755],{"trials":829,"activeCount":95},[],{"intervention":755,"totalTrials":127,"cells":831},{"EARLY_PHASE1":832,"PHASE1":834,"PHASE2":836,"PHASE3":838,"PHASE4":840,"NA":846},{"trials":833,"activeCount":95},[],{"trials":835,"activeCount":95},[],{"trials":837,"activeCount":95},[],{"trials":839,"activeCount":95},[],{"trials":841,"activeCount":95},[842],{"nctId":741,"briefTitle":742,"status":252,"phases":843,"primaryCompletion":744,"completion":745,"start":746,"enrollment":747,"conditions":844,"interventions":845},[87],[749],[728,751,752,753,754,755],{"trials":847,"activeCount":95},[],{"intervention":849,"totalTrials":127,"cells":850},"Beclomethasone",{"EARLY_PHASE1":851,"PHASE1":853,"PHASE2":855,"PHASE3":857,"PHASE4":859,"NA":874},{"trials":852,"activeCount":95},[],{"trials":854,"activeCount":95},[],{"trials":856,"activeCount":95},[],{"trials":858,"activeCount":95},[],{"trials":860,"activeCount":95},[861],{"nctId":862,"briefTitle":863,"status":103,"phases":864,"primaryCompletion":865,"completion":866,"start":867,"enrollment":868,"conditions":869,"interventions":873},"NCT01265342","Efficacy of Nebulised Beclometasone in Viral Wheezing Prophylaxis",[87],"2012-03","2012-10","2010-10",576,[870,871,872],"Bronchial Spasm","Respiratory Sounds","Respiratory Tract Infections",[849],{"trials":875,"activeCount":95},[],{"intervention":877,"totalTrials":127,"cells":878},"Everolimus",{"EARLY_PHASE1":879,"PHASE1":881,"PHASE2":883,"PHASE3":885,"PHASE4":887,"NA":899},{"trials":880,"activeCount":95},[],{"trials":882,"activeCount":95},[],{"trials":884,"activeCount":95},[],{"trials":886,"activeCount":95},[],{"trials":888,"activeCount":95},[889],{"nctId":890,"briefTitle":891,"status":252,"phases":892,"primaryCompletion":893,"completion":893,"start":894,"enrollment":895,"conditions":896,"interventions":898},"NCT02338570","Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus (ORCHIDEE)",[87],"2018-02","2015-07",31,[897],"Renal Cell Carcinoma",[877],{"trials":900,"activeCount":95},[],{"intervention":902,"totalTrials":127,"cells":903},"mycophenolate mofetil",{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":910,"PHASE4":912,"NA":925},{"trials":905,"activeCount":95},[],{"trials":907,"activeCount":95},[],{"trials":909,"activeCount":95},[],{"trials":911,"activeCount":95},[],{"trials":913,"activeCount":95},[914],{"nctId":915,"briefTitle":916,"status":103,"phases":917,"primaryCompletion":918,"completion":919,"start":920,"enrollment":921,"conditions":922,"interventions":923},"NCT00494741","MMF vs. AZA for Kidney Transplantation",[87],"2016-07","2017-11-29","2007-05",233,[28],[902,924],"azathioprine",{"trials":926,"activeCount":95},[],{"intervention":924,"totalTrials":127,"cells":928},{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":933,"PHASE3":935,"PHASE4":937,"NA":943},{"trials":930,"activeCount":95},[],{"trials":932,"activeCount":95},[],{"trials":934,"activeCount":95},[],{"trials":936,"activeCount":95},[],{"trials":938,"activeCount":95},[939],{"nctId":915,"briefTitle":916,"status":103,"phases":940,"primaryCompletion":918,"completion":919,"start":920,"enrollment":921,"conditions":941,"interventions":942},[87],[28],[902,924],{"trials":944,"activeCount":95},[],{"intervention":946,"totalTrials":127,"cells":947},"Aripiprazole",{"EARLY_PHASE1":948,"PHASE1":950,"PHASE2":952,"PHASE3":954,"PHASE4":956,"NA":971},{"trials":949,"activeCount":95},[],{"trials":951,"activeCount":95},[],{"trials":953,"activeCount":95},[],{"trials":955,"activeCount":95},[],{"trials":957,"activeCount":95},[958],{"nctId":959,"briefTitle":960,"status":103,"phases":961,"primaryCompletion":962,"completion":963,"start":964,"enrollment":965,"conditions":966,"interventions":968},"NCT01052389","Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of Schizophrenia",[87],"2012-06","2013-06","2007-07",300,[967],"Schizophrenia",[946,969,970],"Olanzapine","Haloperidol",{"trials":972,"activeCount":95},[],{"intervention":969,"totalTrials":127,"cells":974},{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":979,"PHASE3":981,"PHASE4":983,"NA":989},{"trials":976,"activeCount":95},[],{"trials":978,"activeCount":95},[],{"trials":980,"activeCount":95},[],{"trials":982,"activeCount":95},[],{"trials":984,"activeCount":95},[985],{"nctId":959,"briefTitle":960,"status":103,"phases":986,"primaryCompletion":962,"completion":963,"start":964,"enrollment":965,"conditions":987,"interventions":988},[87],[967],[946,969,970],{"trials":990,"activeCount":95},[],{"intervention":970,"totalTrials":127,"cells":992},{"EARLY_PHASE1":993,"PHASE1":995,"PHASE2":997,"PHASE3":999,"PHASE4":1001,"NA":1007},{"trials":994,"activeCount":95},[],{"trials":996,"activeCount":95},[],{"trials":998,"activeCount":95},[],{"trials":1000,"activeCount":95},[],{"trials":1002,"activeCount":95},[1003],{"nctId":959,"briefTitle":960,"status":103,"phases":1004,"primaryCompletion":962,"completion":963,"start":964,"enrollment":965,"conditions":1005,"interventions":1006},[87],[967],[946,969,970],{"trials":1008,"activeCount":95},[],{"intervention":1010,"totalTrials":24,"cells":1011},"Trabectedin",{"EARLY_PHASE1":1012,"PHASE1":1014,"PHASE2":1016,"PHASE3":1052,"PHASE4":1066,"NA":1068},{"trials":1013,"activeCount":95},[],{"trials":1015,"activeCount":95},[],{"trials":1017,"activeCount":95},[1018,1028,1040],{"nctId":1019,"briefTitle":1020,"status":103,"phases":1021,"primaryCompletion":1022,"completion":1022,"start":1023,"enrollment":1024,"conditions":1025,"interventions":1027},"NCT02194231","ATREUS - Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)",[85],"2019-12-12","2013-07",145,[1026],"Malignant Pleural Mesothelioma",[1010],{"nctId":1029,"briefTitle":1030,"status":103,"phases":1031,"primaryCompletion":1032,"completion":1032,"start":1033,"enrollment":1034,"conditions":1035,"interventions":1037},"NCT02249702","Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma",[85],"2017-04-30","2010-04",168,[1036],"Leiomyosarcoma",[1038,1039],"gemcitabine + docetaxel","trabectedin",{"nctId":1041,"briefTitle":1042,"status":103,"phases":1043,"primaryCompletion":1044,"completion":1044,"start":1045,"enrollment":211,"conditions":1046,"interventions":1050},"NCT04794127","Study on Trabectedin in Combination With Pioglitazone in Patients Myxoid Liposarcomas With Stable Disease After T Alone.",[85],"2024-09-23","2022-02-02",[1047,1048,1049],"Liposarcoma, Myxoid","Liposarcoma, Dedifferentiated","Liposarcoma, Round Cell",[1010,1051],"Pioglitazone Oral Product",{"trials":1053,"activeCount":95},[1054],{"nctId":1055,"briefTitle":1056,"status":103,"phases":1057,"primaryCompletion":1058,"completion":1058,"start":1059,"enrollment":1060,"conditions":1061,"interventions":1063},"NCT01379989","INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer",[86],"2020-12-17","2011-06",617,[1062],"Ovarian Cancer",[1064,1065,1010],"Carboplatin","Pegylated Lipoxomal Doxorubicin",{"trials":1067,"activeCount":95},[],{"trials":1069,"activeCount":95},[],{"intervention":1071,"totalTrials":91,"cells":1072},"Benazepril",{"EARLY_PHASE1":1073,"PHASE1":1075,"PHASE2":1077,"PHASE3":1079,"PHASE4":1100,"NA":1102},{"trials":1074,"activeCount":95},[],{"trials":1076,"activeCount":95},[],{"trials":1078,"activeCount":95},[],{"trials":1080,"activeCount":95},[1081,1092],{"nctId":1082,"briefTitle":1083,"status":103,"phases":1084,"primaryCompletion":918,"completion":1085,"start":920,"enrollment":1086,"conditions":1087,"interventions":1089},"NCT00503152","Preventing Microalbuminuria in Type 2 Diabetes",[86],"2016-09",612,[1088],"Diabetes",[1071,1090,1091],"Valsartan","Benazepril\u002FValsartan",{"nctId":1093,"briefTitle":1094,"status":103,"phases":1095,"primaryCompletion":1096,"completion":1096,"start":920,"enrollment":1097,"conditions":1098,"interventions":1099},"NCT00494715","Preventing ESRD in Overt Nephropathy of Type 2 Diabetes",[86],"2016-04",102,[1088],[1071,1090,1091],{"trials":1101,"activeCount":95},[],{"trials":1103,"activeCount":95},[],{"intervention":1090,"totalTrials":91,"cells":1105},{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1110,"PHASE3":1112,"PHASE4":1122,"NA":1124},{"trials":1107,"activeCount":95},[],{"trials":1109,"activeCount":95},[],{"trials":1111,"activeCount":95},[],{"trials":1113,"activeCount":95},[1114,1118],{"nctId":1082,"briefTitle":1083,"status":103,"phases":1115,"primaryCompletion":918,"completion":1085,"start":920,"enrollment":1086,"conditions":1116,"interventions":1117},[86],[1088],[1071,1090,1091],{"nctId":1093,"briefTitle":1094,"status":103,"phases":1119,"primaryCompletion":1096,"completion":1096,"start":920,"enrollment":1097,"conditions":1120,"interventions":1121},[86],[1088],[1071,1090,1091],{"trials":1123,"activeCount":95},[],{"trials":1125,"activeCount":95},[],{"intervention":1091,"totalTrials":91,"cells":1127},{"EARLY_PHASE1":1128,"PHASE1":1130,"PHASE2":1132,"PHASE3":1134,"PHASE4":1144,"NA":1146},{"trials":1129,"activeCount":95},[],{"trials":1131,"activeCount":95},[],{"trials":1133,"activeCount":95},[],{"trials":1135,"activeCount":95},[1136,1140],{"nctId":1082,"briefTitle":1083,"status":103,"phases":1137,"primaryCompletion":918,"completion":1085,"start":920,"enrollment":1086,"conditions":1138,"interventions":1139},[86],[1088],[1071,1090,1091],{"nctId":1093,"briefTitle":1094,"status":103,"phases":1141,"primaryCompletion":1096,"completion":1096,"start":920,"enrollment":1097,"conditions":1142,"interventions":1143},[86],[1088],[1071,1090,1091],{"trials":1145,"activeCount":95},[],{"trials":1147,"activeCount":95},[],{"intervention":1149,"totalTrials":91,"cells":1150},"standard therapy",{"EARLY_PHASE1":1151,"PHASE1":1153,"PHASE2":1155,"PHASE3":1171,"PHASE4":1186,"NA":1188},{"trials":1152,"activeCount":95},[],{"trials":1154,"activeCount":95},[],{"trials":1156,"activeCount":95},[1157],{"nctId":1158,"briefTitle":1159,"status":103,"phases":1160,"primaryCompletion":1161,"completion":1162,"start":1163,"enrollment":1164,"conditions":1165,"interventions":1168},"NCT01220050","Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism",[85],"2012-07","2013-02","2009-09",43,[1166,1167],"Renal Transplant","Secondary Hyperparathyroidism",[1169,1170],"Paricalcitol","Standard therapy",{"trials":1172,"activeCount":95},[1173],{"nctId":1174,"briefTitle":1175,"status":103,"phases":1176,"primaryCompletion":1177,"completion":1178,"start":1179,"enrollment":1180,"conditions":1181,"interventions":1184},"NCT00199927","Statins in Proteinuric Nephropathies",[86],"2007-12","2008-03","2003-03",217,[1182,1183,32],"Chronic Nephropathy","Proteinuria",[1185,1149],"Fluvastatin",{"trials":1187,"activeCount":95},[],{"trials":1189,"activeCount":95},[],{"intervention":1191,"totalTrials":91,"cells":1192},"Usual care",{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1197,"PHASE3":1199,"PHASE4":1219,"NA":1221},{"trials":1194,"activeCount":95},[],{"trials":1196,"activeCount":95},[],{"trials":1198,"activeCount":95},[],{"trials":1200,"activeCount":95},[1201,1211],{"nctId":1202,"briefTitle":1203,"status":1204,"phases":1205,"primaryCompletion":1206,"completion":1206,"start":1206,"enrollment":95,"conditions":1207,"interventions":1209},"NCT05249790","Anti-inflammatory Drug Algorithm for COVID-19 Home Treatment","WITHDRAWN",[86],"2022-02-24",[1208],"COVID-19",[1210,1191],"Recommended treatment schedule",{"nctId":1212,"briefTitle":1213,"status":1204,"phases":1214,"primaryCompletion":1215,"completion":1215,"start":1216,"enrollment":95,"conditions":1217,"interventions":1218},"NCT05413642","COVID-19 Algorithm Treatment at Home",[86],"2024-02-06","2023-07-01",[1208],[1210,1191],{"trials":1220,"activeCount":95},[],{"trials":1222,"activeCount":95},[],{"intervention":1224,"totalTrials":91,"cells":1225},"Placebos",{"EARLY_PHASE1":1226,"PHASE1":1228,"PHASE2":1230,"PHASE3":1243,"PHASE4":1256,"NA":1258},{"trials":1227,"activeCount":95},[],{"trials":1229,"activeCount":95},[],{"trials":1231,"activeCount":95},[1232],{"nctId":1233,"briefTitle":1234,"status":1204,"phases":1235,"primaryCompletion":1236,"completion":1237,"start":1238,"enrollment":95,"conditions":1239,"interventions":1241},"NCT03999840","Eculizumab to Cemdisiran Switch in aHUS",[85],"2024-01","2024-03","2021-01",[1240],"Atypical Hemolytic Uremic Syndrome",[1242,1224],"cemdisiran",{"trials":1244,"activeCount":95},[1245],{"nctId":1246,"briefTitle":1247,"status":103,"phases":1248,"primaryCompletion":1249,"completion":1249,"start":1250,"enrollment":1251,"conditions":1252,"interventions":1254},"NCT03603184","Atezolizumab Trial in Endometrial Cancer - AtTEnd",[86],"2025-01-20","2018-10-02",549,[1253],"Endometrial Cancer",[1255,1224,111,1064],"Atezolizumab",{"trials":1257,"activeCount":95},[],{"trials":1259,"activeCount":95},[],{"intervention":1064,"totalTrials":91,"cells":1261},{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1266,"PHASE3":1268,"PHASE4":1278,"NA":1280},{"trials":1263,"activeCount":95},[],{"trials":1265,"activeCount":95},[],{"trials":1267,"activeCount":95},[],{"trials":1269,"activeCount":95},[1270,1274],{"nctId":1055,"briefTitle":1056,"status":103,"phases":1271,"primaryCompletion":1058,"completion":1058,"start":1059,"enrollment":1060,"conditions":1272,"interventions":1273},[86],[1062],[1064,1065,1010],{"nctId":1246,"briefTitle":1247,"status":103,"phases":1275,"primaryCompletion":1249,"completion":1249,"start":1250,"enrollment":1251,"conditions":1276,"interventions":1277},[86],[1253],[1255,1224,111,1064],{"trials":1279,"activeCount":95},[],{"trials":1281,"activeCount":95},[],{"intervention":1283,"totalTrials":91,"cells":1284},"Sirolimus",{"EARLY_PHASE1":1285,"PHASE1":1287,"PHASE2":1289,"PHASE3":1303,"PHASE4":1313,"NA":1315},{"trials":1286,"activeCount":95},[],{"trials":1288,"activeCount":95},[],{"trials":1290,"activeCount":95},[1291],{"nctId":1292,"briefTitle":1293,"status":103,"phases":1294,"primaryCompletion":1295,"completion":1296,"start":1297,"enrollment":1298,"conditions":1299,"interventions":1301},"NCT00491517","Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety",[85],"2009-07","2009-08","2007-03",22,[1300],"Polycystic Kidney",[1283,1302],"conventional therapy",{"trials":1304,"activeCount":95},[1305],{"nctId":1306,"briefTitle":1307,"status":252,"phases":1308,"primaryCompletion":1161,"completion":1161,"start":1309,"enrollment":1310,"conditions":1311,"interventions":1312},"NCT01223755","Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency",[85,86],"2010-09",41,[21],[1283,1302],{"trials":1314,"activeCount":95},[],{"trials":1316,"activeCount":95},[],{"intervention":1302,"totalTrials":91,"cells":1318},{"EARLY_PHASE1":1319,"PHASE1":1321,"PHASE2":1323,"PHASE3":1329,"PHASE4":1335,"NA":1337},{"trials":1320,"activeCount":95},[],{"trials":1322,"activeCount":95},[],{"trials":1324,"activeCount":95},[1325],{"nctId":1292,"briefTitle":1293,"status":103,"phases":1326,"primaryCompletion":1295,"completion":1296,"start":1297,"enrollment":1298,"conditions":1327,"interventions":1328},[85],[1300],[1283,1302],{"trials":1330,"activeCount":95},[1331],{"nctId":1306,"briefTitle":1307,"status":252,"phases":1332,"primaryCompletion":1161,"completion":1161,"start":1309,"enrollment":1310,"conditions":1333,"interventions":1334},[85,86],[21],[1283,1302],{"trials":1336,"activeCount":95},[],{"trials":1338,"activeCount":95},[],{"intervention":111,"totalTrials":91,"cells":1340},{"EARLY_PHASE1":1341,"PHASE1":1343,"PHASE2":1345,"PHASE3":1351,"PHASE4":1357,"NA":1359},{"trials":1342,"activeCount":95},[],{"trials":1344,"activeCount":95},[],{"trials":1346,"activeCount":95},[1347],{"nctId":101,"briefTitle":102,"status":103,"phases":1348,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":1349,"interventions":1350},[85],[109],[111,112,63],{"trials":1352,"activeCount":95},[1353],{"nctId":1246,"briefTitle":1247,"status":103,"phases":1354,"primaryCompletion":1249,"completion":1249,"start":1250,"enrollment":1251,"conditions":1355,"interventions":1356},[86],[1253],[1255,1224,111,1064],{"trials":1358,"activeCount":95},[],{"trials":1360,"activeCount":95},[],{"intervention":1362,"totalTrials":127,"cells":1363},"Rituximab",{"EARLY_PHASE1":1364,"PHASE1":1366,"PHASE2":1368,"PHASE3":1370,"PHASE4":1380,"NA":1382},{"trials":1365,"activeCount":95},[],{"trials":1367,"activeCount":95},[],{"trials":1369,"activeCount":95},[],{"trials":1371,"activeCount":95},[1372],{"nctId":1373,"briefTitle":1374,"status":103,"phases":1375,"primaryCompletion":1376,"completion":1376,"start":1377,"enrollment":9,"conditions":1378,"interventions":1379},"NCT00981838","Rituximab in Multirelapsing Minimal Change Disease (MCD) or Focal Segmental Glomerulosclerosis (FSGS)",[86],"2011-04","2009-04",[23],[1362],{"trials":1381,"activeCount":95},[],{"trials":1383,"activeCount":95},[],{"intervention":1385,"totalTrials":127,"cells":1386},"Acetylcarnitine",{"EARLY_PHASE1":1387,"PHASE1":1389,"PHASE2":1391,"PHASE3":1393,"PHASE4":1404,"NA":1406},{"trials":1388,"activeCount":95},[],{"trials":1390,"activeCount":95},[],{"trials":1392,"activeCount":95},[],{"trials":1394,"activeCount":95},[1395],{"nctId":1396,"briefTitle":1397,"status":252,"phases":1398,"primaryCompletion":1399,"completion":1399,"start":1376,"enrollment":1400,"conditions":1401,"interventions":1403},"NCT01379976","Acetyl-L-carnitine in Combination With a Cisplatin-containing Chemotherapy as First Line Treatment of Advanced or Metastatic Non Small Cell Lung Cancer",[86],"2014-10",107,[1402],"Non Small Cell Lung Cancer",[1385],{"trials":1405,"activeCount":95},[],{"trials":1407,"activeCount":95},[],{"intervention":1185,"totalTrials":127,"cells":1409},{"EARLY_PHASE1":1410,"PHASE1":1412,"PHASE2":1414,"PHASE3":1416,"PHASE4":1422,"NA":1424},{"trials":1411,"activeCount":95},[],{"trials":1413,"activeCount":95},[],{"trials":1415,"activeCount":95},[],{"trials":1417,"activeCount":95},[1418],{"nctId":1174,"briefTitle":1175,"status":103,"phases":1419,"primaryCompletion":1177,"completion":1178,"start":1179,"enrollment":1180,"conditions":1420,"interventions":1421},[86],[1182,1183,32],[1185,1149],{"trials":1423,"activeCount":95},[],{"trials":1425,"activeCount":95},[],{"intervention":1427,"totalTrials":127,"cells":1428},"Cyclosporine A",{"EARLY_PHASE1":1429,"PHASE1":1431,"PHASE2":1433,"PHASE3":1435,"PHASE4":1446,"NA":1448},{"trials":1430,"activeCount":95},[],{"trials":1432,"activeCount":95},[],{"trials":1434,"activeCount":95},[],{"trials":1436,"activeCount":95},[1437],{"nctId":1438,"briefTitle":1439,"status":103,"phases":1440,"primaryCompletion":1399,"completion":1399,"start":1441,"enrollment":1442,"conditions":1443,"interventions":1445},"NCT01650662","CYCLosporinE A in Reperfused Acute Myocardial Infarction",[86],"2012-01",410,[1444],"Acute Myocardial Infarction",[1427],{"trials":1447,"activeCount":95},[],{"trials":1449,"activeCount":95},[],{"intervention":1451,"totalTrials":127,"cells":1452},"Canakinumab",{"EARLY_PHASE1":1453,"PHASE1":1455,"PHASE2":1457,"PHASE3":1459,"PHASE4":1472,"NA":1474},{"trials":1454,"activeCount":95},[],{"trials":1456,"activeCount":95},[],{"trials":1458,"activeCount":95},[],{"trials":1460,"activeCount":95},[1461],{"nctId":1462,"briefTitle":1463,"status":252,"phases":1464,"primaryCompletion":1465,"completion":1466,"start":1467,"enrollment":1468,"conditions":1469,"interventions":1471},"NCT05725343","A Prevention Trial of Canakinumab in Subjects at High Risk for Lung Cancer",[86],"2022-04-03","2022-09-21","2022-02-03",350,[1470],"Lung Cancer",[1451],{"trials":1473,"activeCount":95},[],{"trials":1475,"activeCount":95},[],{"intervention":1477,"totalTrials":127,"cells":1478},"Veltassa Oral Powder Product",{"EARLY_PHASE1":1479,"PHASE1":1481,"PHASE2":1483,"PHASE3":1485,"PHASE4":1496,"NA":1498},{"trials":1480,"activeCount":95},[],{"trials":1482,"activeCount":95},[],{"trials":1484,"activeCount":95},[],{"trials":1486,"activeCount":95},[1487],{"nctId":1488,"briefTitle":1489,"status":252,"phases":1490,"primaryCompletion":1491,"completion":1491,"start":1492,"enrollment":91,"conditions":1493,"interventions":1495},"NCT05786469","Patiromer Trial in CKD Stage IIIB to V",[86],"2024-11-07","2023-08-02",[1494],"Hyperkalemia",[1477],{"trials":1497,"activeCount":95},[],{"trials":1499,"activeCount":95},[],{"intervention":1065,"totalTrials":127,"cells":1501},{"EARLY_PHASE1":1502,"PHASE1":1504,"PHASE2":1506,"PHASE3":1508,"PHASE4":1514,"NA":1516},{"trials":1503,"activeCount":95},[],{"trials":1505,"activeCount":95},[],{"trials":1507,"activeCount":95},[],{"trials":1509,"activeCount":95},[1510],{"nctId":1055,"briefTitle":1056,"status":103,"phases":1511,"primaryCompletion":1058,"completion":1058,"start":1059,"enrollment":1060,"conditions":1512,"interventions":1513},[86],[1062],[1064,1065,1010],{"trials":1515,"activeCount":95},[],{"trials":1517,"activeCount":95},[],{"intervention":1519,"totalTrials":127,"cells":1520},"L-arginine",{"EARLY_PHASE1":1521,"PHASE1":1523,"PHASE2":1525,"PHASE3":1527,"PHASE4":1539,"NA":1541},{"trials":1522,"activeCount":95},[],{"trials":1524,"activeCount":95},[],{"trials":1526,"activeCount":95},[],{"trials":1528,"activeCount":95},[1529],{"nctId":1530,"briefTitle":1531,"status":103,"phases":1532,"completion":1533,"start":1534,"enrollment":1535,"conditions":1536,"interventions":1538},"NCT00157521","L-Arginine in Pre-Eclampsia",[86],"2006-05","2002-09",30,[1537],"Pre-Eclampsia",[1519],{"trials":1540,"activeCount":95},[],{"trials":1542,"activeCount":95},[],{"intervention":1544,"totalTrials":127,"cells":1545},"Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin",{"EARLY_PHASE1":1546,"PHASE1":1548,"PHASE2":1550,"PHASE3":1552,"PHASE4":1566,"NA":1568},{"trials":1547,"activeCount":95},[],{"trials":1549,"activeCount":95},[],{"trials":1551,"activeCount":95},[],{"trials":1553,"activeCount":95},[1554],{"nctId":1555,"briefTitle":1556,"status":103,"phases":1557,"primaryCompletion":1558,"completion":1558,"start":1559,"enrollment":1560,"conditions":1561,"interventions":1564},"NCT01640782","Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach",[86],"2013-01","2005-02",1100,[1562,1563],"Adenocarcinoma of the Stomach","Adenocarcinoma of the Gastroesophageal Junction",[1544,1565],"Leucovorin, 5-Fluorouracil",{"trials":1567,"activeCount":95},[],{"trials":1569,"activeCount":95},[],{"intervention":1565,"totalTrials":127,"cells":1571},{"EARLY_PHASE1":1572,"PHASE1":1574,"PHASE2":1576,"PHASE3":1578,"PHASE4":1584,"NA":1586},{"trials":1573,"activeCount":95},[],{"trials":1575,"activeCount":95},[],{"trials":1577,"activeCount":95},[],{"trials":1579,"activeCount":95},[1580],{"nctId":1555,"briefTitle":1556,"status":103,"phases":1581,"primaryCompletion":1558,"completion":1558,"start":1559,"enrollment":1560,"conditions":1582,"interventions":1583},[86],[1562,1563],[1544,1565],{"trials":1585,"activeCount":95},[],{"trials":1587,"activeCount":95},[],{"intervention":1589,"totalTrials":127,"cells":1590},"acetyl-L-carnitine\u002Fstatin",{"EARLY_PHASE1":1591,"PHASE1":1593,"PHASE2":1595,"PHASE3":1597,"PHASE4":1610,"NA":1612},{"trials":1592,"activeCount":95},[],{"trials":1594,"activeCount":95},[],{"trials":1596,"activeCount":95},[],{"trials":1598,"activeCount":95},[1599],{"nctId":1600,"briefTitle":1601,"status":103,"phases":1602,"primaryCompletion":1603,"completion":1604,"start":1605,"enrollment":1606,"conditions":1607,"interventions":1609},"NCT00984750","Acetyl-L-Carnitine in Type 2 Diabetes",[86],"2012-05","2012-12","2008-04",229,[1608,32],"Diabetes Type 2",[1589],{"trials":1611,"activeCount":95},[],{"trials":1613,"activeCount":95},[],{"intervention":1615,"totalTrials":127,"cells":1616},"ACE inhibitor Ramipril",{"EARLY_PHASE1":1617,"PHASE1":1619,"PHASE2":1621,"PHASE3":1623,"PHASE4":1635,"NA":1637},{"trials":1618,"activeCount":95},[],{"trials":1620,"activeCount":95},[],{"trials":1622,"activeCount":95},[],{"trials":1624,"activeCount":95},[1625],{"nctId":1626,"briefTitle":1627,"status":103,"phases":1628,"primaryCompletion":1096,"completion":1096,"start":1629,"enrollment":1630,"conditions":1631,"interventions":1633},"NCT00985322","Angiotensin-converting-enzyme (ACE) Inhibitors in Hemodialysis",[86],"2009-05",269,[1632,32],"Left Ventricular Hypertrophy",[1615,1634],"non-RAS inhibitor antihypertensive therapy",{"trials":1636,"activeCount":95},[],{"trials":1638,"activeCount":95},[],{"intervention":1634,"totalTrials":127,"cells":1640},{"EARLY_PHASE1":1641,"PHASE1":1643,"PHASE2":1645,"PHASE3":1647,"PHASE4":1653,"NA":1655},{"trials":1642,"activeCount":95},[],{"trials":1644,"activeCount":95},[],{"trials":1646,"activeCount":95},[],{"trials":1648,"activeCount":95},[1649],{"nctId":1626,"briefTitle":1627,"status":103,"phases":1650,"primaryCompletion":1096,"completion":1096,"start":1629,"enrollment":1630,"conditions":1651,"interventions":1652},[86],[1632,32],[1615,1634],{"trials":1654,"activeCount":95},[],{"trials":1656,"activeCount":95},[],{"intervention":1658,"totalTrials":127,"cells":1659},"N-3 Polyunsaturated Fatty Acids",{"EARLY_PHASE1":1660,"PHASE1":1662,"PHASE2":1664,"PHASE3":1666,"PHASE4":1678,"NA":1680},{"trials":1661,"activeCount":95},[],{"trials":1663,"activeCount":95},[],{"trials":1665,"activeCount":95},[],{"trials":1667,"activeCount":95},[1668],{"nctId":1669,"briefTitle":1670,"status":103,"phases":1671,"primaryCompletion":1672,"completion":1672,"start":1673,"enrollment":1674,"conditions":1675,"interventions":1677},"NCT00317707","Risk and Prevention Study: Evaluation of the Efficacy of n-3 PUFA in Subjects at High Cardiovascular Risk",[86],"2011-10","2004-02",12513,[1676],"Cardiovascular Diseases",[1658],{"trials":1679,"activeCount":95},[],{"trials":1681,"activeCount":95},[],{"intervention":1683,"totalTrials":127,"cells":1684},"Octreotide-LAR",{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1689,"PHASE3":1691,"PHASE4":1703,"NA":1705},{"trials":1686,"activeCount":95},[],{"trials":1688,"activeCount":95},[],{"trials":1690,"activeCount":95},[],{"trials":1692,"activeCount":95},[1693],{"nctId":1694,"briefTitle":1695,"status":103,"phases":1696,"primaryCompletion":1697,"completion":1697,"start":1698,"enrollment":1699,"conditions":1700,"interventions":1702},"NCT01377246","Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency",[86],"2017-10-18","2011-05",100,[1701],"Autosomal Dominant Polycystic Kidney Disease",[1683],{"trials":1704,"activeCount":95},[],{"trials":1706,"activeCount":95},[],{"intervention":1708,"totalTrials":127,"cells":1709},"Delapril, Delapril-Manidipine Fixed combination",{"EARLY_PHASE1":1710,"PHASE1":1712,"PHASE2":1714,"PHASE3":1716,"PHASE4":1727,"NA":1729},{"trials":1711,"activeCount":95},[],{"trials":1713,"activeCount":95},[],{"trials":1715,"activeCount":95},[],{"trials":1717,"activeCount":95},[1718],{"nctId":1719,"briefTitle":1720,"status":103,"phases":1721,"completion":1722,"start":1723,"enrollment":1724,"conditions":1725,"interventions":1726},"NCT00157586","Delapril and Manidipine for Nephroprotection in Diabetes (DEMAND)",[86],"2008-06","2002-02",342,[18],[1708],{"trials":1728,"activeCount":95},[],{"trials":1730,"activeCount":95},[],{"intervention":1732,"totalTrials":127,"cells":1733},"Long-acting somatostatin",{"EARLY_PHASE1":1734,"PHASE1":1736,"PHASE2":1738,"PHASE3":1740,"PHASE4":1750,"NA":1752},{"trials":1735,"activeCount":95},[],{"trials":1737,"activeCount":95},[],{"trials":1739,"activeCount":95},[],{"trials":1741,"activeCount":95},[1742],{"nctId":1743,"briefTitle":1744,"status":103,"phases":1745,"primaryCompletion":1441,"completion":1441,"start":1746,"enrollment":1747,"conditions":1748,"interventions":1749},"NCT00309283","Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study",[86],"2006-04",78,[21],[1732],{"trials":1751,"activeCount":95},[],{"trials":1753,"activeCount":95},[],{"intervention":1255,"totalTrials":127,"cells":1755},{"EARLY_PHASE1":1756,"PHASE1":1758,"PHASE2":1760,"PHASE3":1762,"PHASE4":1768,"NA":1770},{"trials":1757,"activeCount":95},[],{"trials":1759,"activeCount":95},[],{"trials":1761,"activeCount":95},[],{"trials":1763,"activeCount":95},[1764],{"nctId":1246,"briefTitle":1247,"status":103,"phases":1765,"primaryCompletion":1249,"completion":1249,"start":1250,"enrollment":1251,"conditions":1766,"interventions":1767},[86],[1253],[1255,1224,111,1064],{"trials":1769,"activeCount":95},[],{"trials":1771,"activeCount":95},[],{"intervention":1773,"totalTrials":91,"cells":1774},"Zoledronate",{"EARLY_PHASE1":1775,"PHASE1":1777,"PHASE2":1779,"PHASE3":1802,"PHASE4":1804,"NA":1806},{"trials":1776,"activeCount":95},[],{"trials":1778,"activeCount":95},[],{"trials":1780,"activeCount":95},[1781,1794],{"nctId":1782,"briefTitle":1783,"status":103,"phases":1784,"primaryCompletion":1785,"completion":1786,"start":1787,"enrollment":1788,"conditions":1789,"interventions":1791},"NCT03358017","Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer",[85],"2021-06-17","2023-07-25","2018-03-05",54,[1790],"Triple Negative Breast Cancer",[1773,1792,1793],"Atorvastatin 80mg","Standard neoadjuvant cht",{"nctId":1795,"briefTitle":1796,"status":252,"phases":1797,"primaryCompletion":1798,"completion":1798,"start":1799,"enrollment":1298,"conditions":1800,"interventions":1801},"NCT02347163","Pre-operative Zoledronate in Triple Negative Breast Cancer",[85],"2018-06-08","2015-02-03",[285],[1773],{"trials":1803,"activeCount":95},[],{"trials":1805,"activeCount":95},[],{"trials":1807,"activeCount":95},[],{"intervention":1809,"totalTrials":91,"cells":1810},"Tolvaptan",{"EARLY_PHASE1":1811,"PHASE1":1813,"PHASE2":1815,"PHASE3":1834,"PHASE4":1836,"NA":1838},{"trials":1812,"activeCount":95},[],{"trials":1814,"activeCount":95},[],{"trials":1816,"activeCount":95},[1817,1825],{"nctId":1818,"briefTitle":1819,"status":252,"phases":1820,"primaryCompletion":1821,"completion":1821,"start":1059,"enrollment":222,"conditions":1822,"interventions":1824},"NCT01386372","Tolvaptan for In-hospital Hyponatremia",[85],"2012-11",[1823],"Hyponatremia",[1809],{"nctId":1826,"briefTitle":1827,"status":103,"phases":1828,"primaryCompletion":1829,"completion":1829,"start":1830,"enrollment":205,"conditions":1831,"interventions":1832},"NCT03541447","Tolvaptan-Octreotide LAR Combination in ADPKD",[85],"2021-12-23","2018-12-12",[1701],[1809,1833],"Octreotide LAR",{"trials":1835,"activeCount":95},[],{"trials":1837,"activeCount":95},[],{"trials":1839,"activeCount":95},[],{"intervention":1841,"totalTrials":91,"cells":1842},"Mesenchymal Stromal Cells",{"EARLY_PHASE1":1843,"PHASE1":1845,"PHASE2":1856,"PHASE3":1869,"PHASE4":1871,"NA":1873},{"trials":1844,"activeCount":95},[],{"trials":1846,"activeCount":95},[1847],{"nctId":1848,"briefTitle":1849,"status":252,"phases":1850,"primaryCompletion":1851,"completion":1851,"start":1852,"enrollment":222,"conditions":1853,"interventions":1855},"NCT02012153","Mesenchymal Stromal Cells in Kidney Transplant Recipients",[84],"2023-05-29","2013-12-04",[1854],"Kidney Transplant Rejection",[1841],{"trials":1857,"activeCount":95},[1858],{"nctId":1859,"briefTitle":1860,"status":252,"phases":1861,"primaryCompletion":1862,"completion":1863,"start":1864,"enrollment":1865,"conditions":1866,"interventions":1868},"NCT02585622","NEPHSTROM for Diabetic Kidney Disease",[84,85],"2022-11-03","2024-01-03","2017-12-11",29,[1867],"Diabetic Kidney Disease",[1841],{"trials":1870,"activeCount":95},[],{"trials":1872,"activeCount":95},[],{"trials":1874,"activeCount":95},[],{"intervention":1169,"totalTrials":91,"cells":1876},{"EARLY_PHASE1":1877,"PHASE1":1879,"PHASE2":1881,"PHASE3":1895,"PHASE4":1897,"NA":1899},{"trials":1878,"activeCount":95},[],{"trials":1880,"activeCount":95},[],{"trials":1882,"activeCount":95},[1883,1891],{"nctId":1884,"briefTitle":1885,"status":103,"phases":1886,"primaryCompletion":894,"completion":894,"start":1887,"enrollment":1888,"conditions":1889,"interventions":1890},"NCT01393808","Salt Intake and Antiproteinuric Effect of Paricalcitol in Type 2 Diabetes",[85],"2011-09",112,[18],[1169],{"nctId":1158,"briefTitle":1159,"status":103,"phases":1892,"primaryCompletion":1161,"completion":1162,"start":1163,"enrollment":1164,"conditions":1893,"interventions":1894},[85],[1166,1167],[1169,1170],{"trials":1896,"activeCount":95},[],{"trials":1898,"activeCount":95},[],{"trials":1900,"activeCount":95},[],{"intervention":1902,"totalTrials":127,"cells":1903},"L-acetylcarnitine",{"EARLY_PHASE1":1904,"PHASE1":1906,"PHASE2":1908,"PHASE3":1919,"PHASE4":1921,"NA":1923},{"trials":1905,"activeCount":95},[],{"trials":1907,"activeCount":95},[],{"trials":1909,"activeCount":95},[1910],{"nctId":1911,"briefTitle":1912,"status":103,"phases":1913,"primaryCompletion":1914,"completion":1915,"start":1673,"enrollment":1164,"conditions":1916,"interventions":1918},"NCT00393770","Acetylcarnitine and Insulin Sensitivity",[85],"2006-10","2007-09",[1917],"Type 2 Diabetes Mellitus",[1902],{"trials":1920,"activeCount":95},[],{"trials":1922,"activeCount":95},[],{"trials":1924,"activeCount":95},[],{"intervention":1792,"totalTrials":127,"cells":1926},{"EARLY_PHASE1":1927,"PHASE1":1929,"PHASE2":1931,"PHASE3":1937,"PHASE4":1939,"NA":1941},{"trials":1928,"activeCount":95},[],{"trials":1930,"activeCount":95},[],{"trials":1932,"activeCount":95},[1933],{"nctId":1782,"briefTitle":1783,"status":103,"phases":1934,"primaryCompletion":1785,"completion":1786,"start":1787,"enrollment":1788,"conditions":1935,"interventions":1936},[85],[1790],[1773,1792,1793],{"trials":1938,"activeCount":95},[],{"trials":1940,"activeCount":95},[],{"trials":1942,"activeCount":95},[],{"intervention":1793,"totalTrials":127,"cells":1944},{"EARLY_PHASE1":1945,"PHASE1":1947,"PHASE2":1949,"PHASE3":1955,"PHASE4":1957,"NA":1959},{"trials":1946,"activeCount":95},[],{"trials":1948,"activeCount":95},[],{"trials":1950,"activeCount":95},[1951],{"nctId":1782,"briefTitle":1783,"status":103,"phases":1952,"primaryCompletion":1785,"completion":1786,"start":1787,"enrollment":1788,"conditions":1953,"interventions":1954},[85],[1790],[1773,1792,1793],{"trials":1956,"activeCount":95},[],{"trials":1958,"activeCount":95},[],{"trials":1960,"activeCount":95},[],{"intervention":1962,"totalTrials":127,"cells":1963},"all-trans retinoic acid",{"EARLY_PHASE1":1964,"PHASE1":1966,"PHASE2":1968,"PHASE3":1980,"PHASE4":1982,"NA":1984},{"trials":1965,"activeCount":95},[],{"trials":1967,"activeCount":95},[],{"trials":1969,"activeCount":95},[1970],{"nctId":1971,"briefTitle":1972,"status":252,"phases":1973,"primaryCompletion":254,"completion":254,"start":1974,"enrollment":1975,"conditions":1976,"interventions":1978},"NCT04113863","Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer",[85],"2019-06-18",76,[1977],"Breast Neoplasm Female",[1962,1979],"Anastrozole 1mg",{"trials":1981,"activeCount":95},[],{"trials":1983,"activeCount":95},[],{"trials":1985,"activeCount":95},[],{"intervention":1979,"totalTrials":127,"cells":1987},{"EARLY_PHASE1":1988,"PHASE1":1990,"PHASE2":1992,"PHASE3":1998,"PHASE4":2000,"NA":2002},{"trials":1989,"activeCount":95},[],{"trials":1991,"activeCount":95},[],{"trials":1993,"activeCount":95},[1994],{"nctId":1971,"briefTitle":1972,"status":252,"phases":1995,"primaryCompletion":254,"completion":254,"start":1974,"enrollment":1975,"conditions":1996,"interventions":1997},[85],[1977],[1962,1979],{"trials":1999,"activeCount":95},[],{"trials":2001,"activeCount":95},[],{"trials":2003,"activeCount":95},[],{"intervention":1833,"totalTrials":127,"cells":2005},{"EARLY_PHASE1":2006,"PHASE1":2008,"PHASE2":2010,"PHASE3":2016,"PHASE4":2018,"NA":2020},{"trials":2007,"activeCount":95},[],{"trials":2009,"activeCount":95},[],{"trials":2011,"activeCount":95},[2012],{"nctId":1826,"briefTitle":1827,"status":103,"phases":2013,"primaryCompletion":1829,"completion":1829,"start":1830,"enrollment":205,"conditions":2014,"interventions":2015},[85],[1701],[1809,1833],{"trials":2017,"activeCount":95},[],{"trials":2019,"activeCount":95},[],{"trials":2021,"activeCount":95},[],{"intervention":2023,"totalTrials":127,"cells":2024},"Campath-1H",{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2029,"PHASE3":2038,"PHASE4":2040,"NA":2042},{"trials":2026,"activeCount":95},[],{"trials":2028,"activeCount":95},[],{"trials":2030,"activeCount":95},[2031],{"nctId":2032,"briefTitle":2033,"status":103,"phases":2034,"completion":1033,"start":2035,"enrollment":244,"conditions":2036,"interventions":2037},"NCT00309270","Low Dose Sirolimus or CsA-Based Maintenance Immunosuppression After Induction With Campath-1 in Kidney Transplantation",[85],"2003-02",[28],[2023],{"trials":2039,"activeCount":95},[],{"trials":2041,"activeCount":95},[],{"trials":2043,"activeCount":95},[],{"intervention":2045,"totalTrials":127,"cells":2046},"Vinorelbine Tartrate",{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2051,"PHASE3":2062,"PHASE4":2064,"NA":2066},{"trials":2048,"activeCount":95},[],{"trials":2050,"activeCount":95},[],{"trials":2052,"activeCount":95},[2053],{"nctId":2054,"briefTitle":2055,"status":252,"phases":2056,"primaryCompletion":2057,"completion":2057,"start":2058,"enrollment":24,"conditions":2059,"interventions":2060},"NCT03358004","the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment",[85],"2018-09-13","2017-06-14",[1790],[2045,2061],"Capecitabine 500 MG",{"trials":2063,"activeCount":95},[],{"trials":2065,"activeCount":95},[],{"trials":2067,"activeCount":95},[],{"intervention":2061,"totalTrials":127,"cells":2069},{"EARLY_PHASE1":2070,"PHASE1":2072,"PHASE2":2074,"PHASE3":2080,"PHASE4":2082,"NA":2084},{"trials":2071,"activeCount":95},[],{"trials":2073,"activeCount":95},[],{"trials":2075,"activeCount":95},[2076],{"nctId":2054,"briefTitle":2055,"status":252,"phases":2077,"primaryCompletion":2057,"completion":2057,"start":2058,"enrollment":24,"conditions":2078,"interventions":2079},[85],[1790],[2045,2061],{"trials":2081,"activeCount":95},[],{"trials":2083,"activeCount":95},[],{"trials":2085,"activeCount":95},[],{"intervention":2087,"totalTrials":127,"cells":2088},"Ortataxel",{"EARLY_PHASE1":2089,"PHASE1":2091,"PHASE2":2093,"PHASE3":2106,"PHASE4":2108,"NA":2110},{"trials":2090,"activeCount":95},[],{"trials":2092,"activeCount":95},[],{"trials":2094,"activeCount":95},[2095],{"nctId":2096,"briefTitle":2097,"status":103,"phases":2098,"primaryCompletion":2099,"completion":2100,"start":2101,"enrollment":2102,"conditions":2103,"interventions":2105},"NCT01989884","An Efficacy Study Of Ortataxel In Recurrent Glioblastoma",[85],"2015-12","2016-12","2013-11",45,[2104],"Glioblastoma",[2087],{"trials":2107,"activeCount":95},[],{"trials":2109,"activeCount":95},[],{"trials":2111,"activeCount":95},[],{"intervention":2113,"totalTrials":127,"cells":2114},"Telmisartan",{"EARLY_PHASE1":2115,"PHASE1":2117,"PHASE2":2119,"PHASE3":2130,"PHASE4":2132,"NA":2134},{"trials":2116,"activeCount":95},[],{"trials":2118,"activeCount":95},[],{"trials":2120,"activeCount":95},[2121],{"nctId":2122,"briefTitle":2123,"status":103,"phases":2124,"primaryCompletion":963,"completion":2125,"start":2126,"enrollment":205,"conditions":2127,"interventions":2128},"NCT01224860","Telmisartan Versus Losartan in Kidney Transplantation",[85],"2014-01","2009-01",[1166],[2113,2129],"Losartan",{"trials":2131,"activeCount":95},[],{"trials":2133,"activeCount":95},[],{"trials":2135,"activeCount":95},[],{"intervention":2129,"totalTrials":127,"cells":2137},{"EARLY_PHASE1":2138,"PHASE1":2140,"PHASE2":2142,"PHASE3":2148,"PHASE4":2150,"NA":2152},{"trials":2139,"activeCount":95},[],{"trials":2141,"activeCount":95},[],{"trials":2143,"activeCount":95},[2144],{"nctId":2122,"briefTitle":2123,"status":103,"phases":2145,"primaryCompletion":963,"completion":2125,"start":2126,"enrollment":205,"conditions":2146,"interventions":2147},[85],[1166],[2113,2129],{"trials":2149,"activeCount":95},[],{"trials":2151,"activeCount":95},[],{"trials":2153,"activeCount":95},[],{"intervention":2155,"totalTrials":127,"cells":2156},"MOR202",{"EARLY_PHASE1":2157,"PHASE1":2159,"PHASE2":2161,"PHASE3":2171,"PHASE4":2173,"NA":2175},{"trials":2158,"activeCount":95},[],{"trials":2160,"activeCount":95},[],{"trials":2162,"activeCount":95},[2163],{"nctId":2164,"briefTitle":2165,"status":103,"phases":2166,"primaryCompletion":2167,"completion":2167,"start":2168,"enrollment":211,"conditions":2169,"interventions":2170},"NCT04893096","MOR202 for Refractory MN",[85],"2025-02-21","2021-10-22",[15],[2155],{"trials":2172,"activeCount":95},[],{"trials":2174,"activeCount":95},[],{"trials":2176,"activeCount":95},[],{"intervention":1038,"totalTrials":127,"cells":2178},{"EARLY_PHASE1":2179,"PHASE1":2181,"PHASE2":2183,"PHASE3":2189,"PHASE4":2191,"NA":2193},{"trials":2180,"activeCount":95},[],{"trials":2182,"activeCount":95},[],{"trials":2184,"activeCount":95},[2185],{"nctId":1029,"briefTitle":1030,"status":103,"phases":2186,"primaryCompletion":1032,"completion":1032,"start":1033,"enrollment":1034,"conditions":2187,"interventions":2188},[85],[1036],[1038,1039],{"trials":2190,"activeCount":95},[],{"trials":2192,"activeCount":95},[],{"trials":2194,"activeCount":95},[],{"intervention":2196,"totalTrials":127,"cells":2197},"Insulin",{"EARLY_PHASE1":2198,"PHASE1":2200,"PHASE2":2202,"PHASE3":2214,"PHASE4":2216,"NA":2218},{"trials":2199,"activeCount":95},[],{"trials":2201,"activeCount":95},[],{"trials":2203,"activeCount":95},[2204],{"nctId":2205,"briefTitle":2206,"status":252,"phases":2207,"primaryCompletion":2208,"completion":2208,"start":2209,"enrollment":211,"conditions":2210,"interventions":2213},"NCT03665350","Insulin Treatment in Diabetic Older People With Heart Failure.",[85],"2019-09-18","2018-11-08",[2211,2212],"Heart Failure","Diabetes Mellitus, Type 2",[2196],{"trials":2215,"activeCount":95},[],{"trials":2217,"activeCount":95},[],{"trials":2219,"activeCount":95},[],{"intervention":2221,"totalTrials":127,"cells":2222},"Ezetimibe",{"EARLY_PHASE1":2223,"PHASE1":2225,"PHASE2":2227,"PHASE3":2239,"PHASE4":2241,"NA":2243},{"trials":2224,"activeCount":95},[],{"trials":2226,"activeCount":95},[],{"trials":2228,"activeCount":95},[2229],{"nctId":2230,"briefTitle":2231,"status":103,"phases":2232,"completion":2233,"start":2234,"enrollment":2235,"conditions":2236,"interventions":2237},"NCT00157482","Ezetimibe and Simvastatin in Dyslipidemia of Diabetes",[85],"2006-12","2005-01",108,[18],[2221,2238],"Simvastatin",{"trials":2240,"activeCount":95},[],{"trials":2242,"activeCount":95},[],{"trials":2244,"activeCount":95},[],{"intervention":2238,"totalTrials":127,"cells":2246},{"EARLY_PHASE1":2247,"PHASE1":2249,"PHASE2":2251,"PHASE3":2257,"PHASE4":2259,"NA":2261},{"trials":2248,"activeCount":95},[],{"trials":2250,"activeCount":95},[],{"trials":2252,"activeCount":95},[2253],{"nctId":2230,"briefTitle":2231,"status":103,"phases":2254,"completion":2233,"start":2234,"enrollment":2235,"conditions":2255,"interventions":2256},[85],[18],[2221,2238],{"trials":2258,"activeCount":95},[],{"trials":2260,"activeCount":95},[],{"trials":2262,"activeCount":95},[],{"intervention":1051,"totalTrials":127,"cells":2264},{"EARLY_PHASE1":2265,"PHASE1":2267,"PHASE2":2269,"PHASE3":2275,"PHASE4":2277,"NA":2279},{"trials":2266,"activeCount":95},[],{"trials":2268,"activeCount":95},[],{"trials":2270,"activeCount":95},[2271],{"nctId":1041,"briefTitle":1042,"status":103,"phases":2272,"primaryCompletion":1044,"completion":1044,"start":1045,"enrollment":211,"conditions":2273,"interventions":2274},[85],[1047,1048,1049],[1010,1051],{"trials":2276,"activeCount":95},[],{"trials":2278,"activeCount":95},[],{"trials":2280,"activeCount":95},[],{"intervention":1242,"totalTrials":127,"cells":2282},{"EARLY_PHASE1":2283,"PHASE1":2285,"PHASE2":2287,"PHASE3":2293,"PHASE4":2295,"NA":2297},{"trials":2284,"activeCount":95},[],{"trials":2286,"activeCount":95},[],{"trials":2288,"activeCount":95},[2289],{"nctId":1233,"briefTitle":1234,"status":1204,"phases":2290,"primaryCompletion":1236,"completion":1237,"start":1238,"enrollment":95,"conditions":2291,"interventions":2292},[85],[1240],[1242,1224],{"trials":2294,"activeCount":95},[],{"trials":2296,"activeCount":95},[],{"trials":2298,"activeCount":95},[],{"intervention":2300,"totalTrials":127,"cells":2301},"Dapagliflozin 10Mg Tab",{"EARLY_PHASE1":2302,"PHASE1":2304,"PHASE2":2306,"PHASE3":2318,"PHASE4":2320,"NA":2322},{"trials":2303,"activeCount":95},[],{"trials":2305,"activeCount":95},[],{"trials":2307,"activeCount":95},[2308],{"nctId":2309,"briefTitle":2310,"status":103,"phases":2311,"primaryCompletion":2312,"completion":2312,"start":2313,"enrollment":2314,"conditions":2315,"interventions":2317},"NCT04794517","Dapagliflozin in Non-diabetic Stage IV CKD",[85],"2024-05-07","2021-11-08",32,[2316],"Chronic Kidney Diseases",[2300],{"trials":2319,"activeCount":95},[],{"trials":2321,"activeCount":95},[],{"trials":2323,"activeCount":95},[],{"intervention":2325,"totalTrials":127,"cells":2326},"Niraparib",{"EARLY_PHASE1":2327,"PHASE1":2329,"PHASE2":2331,"PHASE3":2344,"PHASE4":2346,"NA":2348},{"trials":2328,"activeCount":95},[],{"trials":2330,"activeCount":95},[],{"trials":2332,"activeCount":95},[2333],{"nctId":2334,"briefTitle":2335,"status":252,"phases":2336,"primaryCompletion":2337,"completion":2337,"start":2338,"enrollment":2339,"conditions":2340,"interventions":2343},"NCT03891576","Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)",[85],"2024-08-31","2019-11-13",83,[1062,2341,2342],"Fallopian Tube Cancer","Primary Peritoneal Carcinoma",[2325],{"trials":2345,"activeCount":95},[],{"trials":2347,"activeCount":95},[],{"trials":2349,"activeCount":95},[],{"intervention":2351,"totalTrials":127,"cells":2352},"RNS60",{"EARLY_PHASE1":2353,"PHASE1":2355,"PHASE2":2357,"PHASE3":2369,"PHASE4":2371,"NA":2373},{"trials":2354,"activeCount":95},[],{"trials":2356,"activeCount":95},[],{"trials":2358,"activeCount":95},[2359],{"nctId":2360,"briefTitle":2361,"status":103,"phases":2362,"primaryCompletion":2363,"completion":2364,"start":2365,"enrollment":2366,"conditions":2367,"interventions":2368},"NCT03456882","The Effect of RNS60 on ALS Biomarkers",[85],"2020-11-23","2021-05-30","2017-05-30",147,[188],[2351],{"trials":2370,"activeCount":95},[],{"trials":2372,"activeCount":95},[],{"trials":2374,"activeCount":95},[],{"intervention":112,"totalTrials":127,"cells":2376},{"EARLY_PHASE1":2377,"PHASE1":2379,"PHASE2":2381,"PHASE3":2387,"PHASE4":2389,"NA":2391},{"trials":2378,"activeCount":95},[],{"trials":2380,"activeCount":95},[],{"trials":2382,"activeCount":95},[2383],{"nctId":101,"briefTitle":102,"status":103,"phases":2384,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":2385,"interventions":2386},[85],[109],[111,112,63],{"trials":2388,"activeCount":95},[],{"trials":2390,"activeCount":95},[],{"trials":2392,"activeCount":95},[],{"intervention":2394,"totalTrials":127,"cells":2395},"bevacizumab and trabectedin",{"EARLY_PHASE1":2396,"PHASE1":2398,"PHASE2":2400,"PHASE3":2412,"PHASE4":2414,"NA":2416},{"trials":2397,"activeCount":95},[],{"trials":2399,"activeCount":95},[],{"trials":2401,"activeCount":95},[2402],{"nctId":2403,"briefTitle":2404,"status":103,"phases":2405,"primaryCompletion":2406,"completion":2406,"start":1023,"enrollment":2407,"conditions":2408,"interventions":2410},"NCT01735071","Bevacizumab and Trabectedin +\u002F- Carboplatin in Advanced Ovarian Cancer",[85],"2018-03-18",71,[2409],"Ovarian Epithelial Cancer Recurrent",[2394,2411],"bevacizumab, trabectedin and carboplatin",{"trials":2413,"activeCount":95},[],{"trials":2415,"activeCount":95},[],{"trials":2417,"activeCount":95},[],{"intervention":2411,"totalTrials":127,"cells":2419},{"EARLY_PHASE1":2420,"PHASE1":2422,"PHASE2":2424,"PHASE3":2430,"PHASE4":2432,"NA":2434},{"trials":2421,"activeCount":95},[],{"trials":2423,"activeCount":95},[],{"trials":2425,"activeCount":95},[2426],{"nctId":2403,"briefTitle":2404,"status":103,"phases":2427,"primaryCompletion":2406,"completion":2406,"start":1023,"enrollment":2407,"conditions":2428,"interventions":2429},[85],[2409],[2394,2411],{"trials":2431,"activeCount":95},[],{"trials":2433,"activeCount":95},[],{"trials":2435,"activeCount":95},[],{"intervention":2437,"totalTrials":127,"cells":2438},"Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil",{"EARLY_PHASE1":2439,"PHASE1":2441,"PHASE2":2443,"PHASE3":2454,"PHASE4":2456,"NA":2458},{"trials":2440,"activeCount":95},[],{"trials":2442,"activeCount":95},[],{"trials":2444,"activeCount":95},[2445],{"nctId":2446,"briefTitle":2447,"status":252,"phases":2448,"primaryCompletion":1023,"completion":2449,"start":2450,"enrollment":24,"conditions":2451,"interventions":2452},"NCT00752479","Mesenchymal Stem Cells Under Basiliximab\u002FLow Dose RATG to Induce Renal Transplant Tolerance",[84,85],"2013-12","2008-05",[28],[2437,2453],"Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil",{"trials":2455,"activeCount":95},[],{"trials":2457,"activeCount":95},[],{"trials":2459,"activeCount":95},[],{"intervention":2453,"totalTrials":127,"cells":2461},{"EARLY_PHASE1":2462,"PHASE1":2464,"PHASE2":2466,"PHASE3":2472,"PHASE4":2474,"NA":2476},{"trials":2463,"activeCount":95},[],{"trials":2465,"activeCount":95},[],{"trials":2467,"activeCount":95},[2468],{"nctId":2446,"briefTitle":2447,"status":252,"phases":2469,"primaryCompletion":1023,"completion":2449,"start":2450,"enrollment":24,"conditions":2470,"interventions":2471},[84,85],[28],[2437,2453],{"trials":2473,"activeCount":95},[],{"trials":2475,"activeCount":95},[],{"trials":2477,"activeCount":95},[],{"intervention":259,"totalTrials":127,"cells":2479},{"EARLY_PHASE1":2480,"PHASE1":2482,"PHASE2":2484,"PHASE3":2490,"PHASE4":2492,"NA":2494},{"trials":2481,"activeCount":95},[],{"trials":2483,"activeCount":95},[],{"trials":2485,"activeCount":95},[2486],{"nctId":250,"briefTitle":251,"status":252,"phases":2487,"primaryCompletion":254,"completion":254,"start":255,"enrollment":211,"conditions":2488,"interventions":2489},[85],[257],[259,260,261],{"trials":2491,"activeCount":95},[],{"trials":2493,"activeCount":95},[],{"trials":2495,"activeCount":95},[],{"intervention":260,"totalTrials":127,"cells":2497},{"EARLY_PHASE1":2498,"PHASE1":2500,"PHASE2":2502,"PHASE3":2508,"PHASE4":2510,"NA":2512},{"trials":2499,"activeCount":95},[],{"trials":2501,"activeCount":95},[],{"trials":2503,"activeCount":95},[2504],{"nctId":250,"briefTitle":251,"status":252,"phases":2505,"primaryCompletion":254,"completion":254,"start":255,"enrollment":211,"conditions":2506,"interventions":2507},[85],[257],[259,260,261],{"trials":2509,"activeCount":95},[],{"trials":2511,"activeCount":95},[],{"trials":2513,"activeCount":95},[],{"intervention":2515,"totalTrials":127,"cells":2516},"ACE I, ATA II and Statins",{"EARLY_PHASE1":2517,"PHASE1":2519,"PHASE2":2521,"PHASE3":2534,"PHASE4":2536,"NA":2538},{"trials":2518,"activeCount":95},[],{"trials":2520,"activeCount":95},[],{"trials":2522,"activeCount":95},[2523],{"nctId":2524,"briefTitle":2525,"status":103,"phases":2526,"primaryCompletion":1722,"completion":2527,"start":2528,"enrollment":2529,"conditions":2530,"interventions":2532},"NCT00309257","Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome",[85],"2009-10","2004-01",9,[2531],"Alport Syndrome",[2515,2533],"Benazepril, Valsartan and Fluvastatin",{"trials":2535,"activeCount":95},[],{"trials":2537,"activeCount":95},[],{"trials":2539,"activeCount":95},[],{"intervention":2533,"totalTrials":127,"cells":2541},{"EARLY_PHASE1":2542,"PHASE1":2544,"PHASE2":2546,"PHASE3":2552,"PHASE4":2554,"NA":2556},{"trials":2543,"activeCount":95},[],{"trials":2545,"activeCount":95},[],{"trials":2547,"activeCount":95},[2548],{"nctId":2524,"briefTitle":2525,"status":103,"phases":2549,"primaryCompletion":1722,"completion":2527,"start":2528,"enrollment":2529,"conditions":2550,"interventions":2551},[85],[2531],[2515,2533],{"trials":2553,"activeCount":95},[],{"trials":2555,"activeCount":95},[],{"trials":2557,"activeCount":95},[],{"intervention":2559,"totalTrials":127,"cells":2560},"CCX168",{"EARLY_PHASE1":2561,"PHASE1":2563,"PHASE2":2565,"PHASE3":2575,"PHASE4":2577,"NA":2579},{"trials":2562,"activeCount":95},[],{"trials":2564,"activeCount":95},[],{"trials":2566,"activeCount":95},[2567],{"nctId":2568,"briefTitle":2569,"status":252,"phases":2570,"primaryCompletion":2571,"completion":2571,"start":2572,"enrollment":16,"conditions":2573,"interventions":2574},"NCT02464891","Complement Inhibition in aHUS Dialysis Patients",[85],"2017-07-13","2015-06-04",[1240],[2559],{"trials":2576,"activeCount":95},[],{"trials":2578,"activeCount":95},[],{"trials":2580,"activeCount":95},[],{"intervention":2582,"totalTrials":127,"cells":2583},"Rosiglitazone",{"EARLY_PHASE1":2584,"PHASE1":2586,"PHASE2":2588,"PHASE3":2597,"PHASE4":2599,"NA":2601},{"trials":2585,"activeCount":95},[],{"trials":2587,"activeCount":95},[],{"trials":2589,"activeCount":95},[2590],{"nctId":2591,"briefTitle":2592,"status":103,"phases":2593,"completion":964,"start":2594,"enrollment":211,"conditions":2595,"interventions":2596},"NCT00309309","Metabolic and Renal Effects of Rosiglitazone in Kidney Transplant",[85],"2005-04",[28],[2582],{"trials":2598,"activeCount":95},[],{"trials":2600,"activeCount":95},[],{"trials":2602,"activeCount":95},[],{"intervention":2604,"totalTrials":127,"cells":2605},"Sevelamer",{"EARLY_PHASE1":2606,"PHASE1":2608,"PHASE2":2610,"PHASE3":2623,"PHASE4":2625,"NA":2627},{"trials":2607,"activeCount":95},[],{"trials":2609,"activeCount":95},[],{"trials":2611,"activeCount":95},[2612],{"nctId":2613,"briefTitle":2614,"status":103,"phases":2615,"primaryCompletion":2616,"completion":2616,"start":2617,"enrollment":2618,"conditions":2619,"interventions":2621},"NCT01968759","Sevelamer in Proteinuric CKD",[85],"2015-10","2013-10",53,[2620],"Chronic Kidney Disease",[2604,2622],"Ramipril and Irbesartan",{"trials":2624,"activeCount":95},[],{"trials":2626,"activeCount":95},[],{"trials":2628,"activeCount":95},[],{"intervention":2622,"totalTrials":127,"cells":2630},{"EARLY_PHASE1":2631,"PHASE1":2633,"PHASE2":2635,"PHASE3":2641,"PHASE4":2643,"NA":2645},{"trials":2632,"activeCount":95},[],{"trials":2634,"activeCount":95},[],{"trials":2636,"activeCount":95},[2637],{"nctId":2613,"briefTitle":2614,"status":103,"phases":2638,"primaryCompletion":2616,"completion":2616,"start":2617,"enrollment":2618,"conditions":2639,"interventions":2640},[85],[2620],[2604,2622],{"trials":2642,"activeCount":95},[],{"trials":2644,"activeCount":95},[],{"trials":2646,"activeCount":95},[],{"intervention":2648,"totalTrials":127,"cells":2649},"Doxycycline Hcl",{"EARLY_PHASE1":2650,"PHASE1":2652,"PHASE2":2654,"PHASE3":2666,"PHASE4":2668,"NA":2670},{"trials":2651,"activeCount":95},[],{"trials":2653,"activeCount":95},[],{"trials":2655,"activeCount":95},[2656],{"nctId":2657,"briefTitle":2658,"status":103,"phases":2659,"primaryCompletion":2660,"completion":2661,"start":2662,"enrollment":1865,"conditions":2663,"interventions":2665},"NCT04846335","Familiar Fatal Insomnia: Preventive Treatment With Doxycycline in Subject With Disease Risk",[85],"2021-04-12","2024-11-30","2011-04-28",[2664],"Familial Fatal Insomnia",[2648],{"trials":2667,"activeCount":95},[],{"trials":2669,"activeCount":95},[],{"trials":2671,"activeCount":95},[],{"intervention":2673,"totalTrials":127,"cells":2674},"Empagliflozin 10 MG",{"EARLY_PHASE1":2675,"PHASE1":2677,"PHASE2":2679,"PHASE3":2690,"PHASE4":2692,"NA":2694},{"trials":2676,"activeCount":95},[],{"trials":2678,"activeCount":95},[],{"trials":2680,"activeCount":95},[2681],{"nctId":2682,"briefTitle":2683,"status":1204,"phases":2684,"primaryCompletion":2685,"completion":2685,"start":2685,"enrollment":95,"conditions":2686,"interventions":2689},"NCT04143581","SGLT2 Inhibitors in Glomerular Hyperfiltration",[85],"2021-09-03",[2687,2688],"Obesity","Non-diabetic Chronic Kidney Disease",[2673],{"trials":2691,"activeCount":95},[],{"trials":2693,"activeCount":95},[],{"trials":2695,"activeCount":95},[],{"intervention":2697,"totalTrials":127,"cells":2698},"nitroaspirin",{"EARLY_PHASE1":2699,"PHASE1":2701,"PHASE2":2703,"PHASE3":2713,"PHASE4":2715,"NA":2717},{"trials":2700,"activeCount":95},[],{"trials":2702,"activeCount":95},[],{"trials":2704,"activeCount":95},[2705],{"nctId":2706,"briefTitle":2707,"status":252,"phases":2708,"completion":2709,"start":1179,"enrollment":11,"conditions":2710,"interventions":2712},"NCT00157508","Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy",[85],"2004-08",[18,2711],"Early Nephropathy",[2697],{"trials":2714,"activeCount":95},[],{"trials":2716,"activeCount":95},[],{"trials":2718,"activeCount":95},[],{"intervention":2720,"totalTrials":127,"cells":2721},"Eculizumab",{"EARLY_PHASE1":2722,"PHASE1":2724,"PHASE2":2726,"PHASE3":2737,"PHASE4":2739,"NA":2741},{"trials":2723,"activeCount":95},[],{"trials":2725,"activeCount":95},[],{"trials":2727,"activeCount":95},[2728],{"nctId":2729,"briefTitle":2730,"status":103,"phases":2731,"primaryCompletion":2732,"completion":2732,"start":2733,"enrollment":211,"conditions":2734,"interventions":2736},"NCT02093533","Eculizumab in Primary MPGN",[85],"2017-12","2014-03",[2735],"Membranoproliferative Glomerulonephritis",[2720],{"trials":2738,"activeCount":95},[],{"trials":2740,"activeCount":95},[],{"trials":2742,"activeCount":95},[],{"intervention":2744,"totalTrials":127,"cells":2745},"Propranolol",{"EARLY_PHASE1":2746,"PHASE1":2748,"PHASE2":2750,"PHASE3":2761,"PHASE4":2763,"NA":2765},{"trials":2747,"activeCount":95},[],{"trials":2749,"activeCount":95},[],{"trials":2751,"activeCount":95},[2752],{"nctId":2753,"briefTitle":2754,"status":103,"phases":2755,"primaryCompletion":2756,"completion":745,"start":2757,"enrollment":2407,"conditions":2758,"interventions":2760},"NCT03589014","Treat_CCM: Propranolol in Familial Cerebral Cavernous Malformation",[85],"2021-10-31","2018-04-11",[2759],"Cerebral Cavernous Malformation",[2744],{"trials":2762,"activeCount":95},[],{"trials":2764,"activeCount":95},[],{"trials":2766,"activeCount":95},[],{"intervention":2768,"totalTrials":127,"cells":2769},"Mesenchymal stromal cell",{"EARLY_PHASE1":2770,"PHASE1":2772,"PHASE2":2784,"PHASE3":2786,"PHASE4":2788,"NA":2790},{"trials":2771,"activeCount":95},[],{"trials":2773,"activeCount":95},[2774],{"nctId":2775,"briefTitle":2776,"status":1204,"phases":2777,"primaryCompletion":2778,"completion":2778,"start":2779,"enrollment":95,"conditions":2780,"interventions":2783},"NCT01275612","Mesenchymal Stem Cells In Cisplatin-Induced Acute Renal Failure In Patients With Solid Organ Cancers",[84],"2018-03-19","2010-11",[2781,2782],"Solid Tumors","Acute Kidney Injury",[2768],{"trials":2785,"activeCount":95},[],{"trials":2787,"activeCount":95},[],{"trials":2789,"activeCount":95},[],{"trials":2791,"activeCount":95},[],{"intervention":1210,"totalTrials":24,"cells":2793},{"EARLY_PHASE1":2794,"PHASE1":2796,"PHASE2":2798,"PHASE3":2800,"PHASE4":2810,"NA":2812},{"trials":2795,"activeCount":95},[],{"trials":2797,"activeCount":95},[],{"trials":2799,"activeCount":95},[],{"trials":2801,"activeCount":95},[2802,2806],{"nctId":1202,"briefTitle":1203,"status":1204,"phases":2803,"primaryCompletion":1206,"completion":1206,"start":1206,"enrollment":95,"conditions":2804,"interventions":2805},[86],[1208],[1210,1191],{"nctId":1212,"briefTitle":1213,"status":1204,"phases":2807,"primaryCompletion":1215,"completion":1215,"start":1216,"enrollment":95,"conditions":2808,"interventions":2809},[86],[1208],[1210,1191],{"trials":2811,"activeCount":95},[],{"trials":2813,"activeCount":95},[2814,2825],{"nctId":2815,"briefTitle":2816,"status":103,"phases":2817,"primaryCompletion":2818,"completion":2818,"start":2819,"enrollment":2820,"conditions":2821,"interventions":2823},"NCT04854824","A Simple Approach to Prevent Hospitalization for COVID-19 Patients",[],"2021-12-21","2021-07-01",216,[2822],"Covid19",[1210,2824],"Control treatment schedule",{"nctId":2826,"briefTitle":2827,"status":103,"phases":2828,"primaryCompletion":2829,"completion":2829,"start":2830,"enrollment":2831,"conditions":2832,"interventions":2834},"NCT04794998","A Simple Approach to Treat COVID-19 Patients at Home.",[],"2021-07-31","2021-02-08",180,[2833],"COVID 19",[1210,2824],{"intervention":2836,"totalTrials":91,"cells":2837},"Morphine",{"EARLY_PHASE1":2838,"PHASE1":2840,"PHASE2":2842,"PHASE3":2844,"PHASE4":2846,"NA":2860},{"trials":2839,"activeCount":95},[],{"trials":2841,"activeCount":95},[],{"trials":2843,"activeCount":95},[],{"trials":2845,"activeCount":95},[],{"trials":2847,"activeCount":95},[2848],{"nctId":2849,"briefTitle":2850,"status":103,"phases":2851,"primaryCompletion":1399,"completion":1399,"start":1376,"enrollment":2852,"conditions":2853,"interventions":2856},"NCT01809106","RCT Comparing the Analgesic Efficacy of 4 Therapeutic Strategies Based on 4 Different Major Opioids (Fentanyl, Oxycodone, Buprenorphine vs Morphine) in Cancer Patients With Moderate\u002FSevere Pain, at the Moment of Starting 3rd Step of WHO Analgesic Ladder.",[87],518,[2854,2855],"Cancer","Cancer Pain",[2836,2857,2858,2859],"Fentanyl","Buprenorphine","Oxycodone",{"trials":2861,"activeCount":95},[2862],{"nctId":2863,"briefTitle":2864,"status":103,"phases":2865,"primaryCompletion":2099,"completion":2099,"start":2866,"enrollment":283,"conditions":2867,"interventions":2871},"NCT01946555","Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain",[],"2013-09",[2868,2855,2869,2870],"Tumor","Breakthrough Cancer Pain","Neuropathic Pain",[2836,2857,2872,2858,2859,2873,2874],"Methadone","Hydromorphone","Tapentadol",{"intervention":2857,"totalTrials":91,"cells":2876},{"EARLY_PHASE1":2877,"PHASE1":2879,"PHASE2":2881,"PHASE3":2883,"PHASE4":2885,"NA":2891},{"trials":2878,"activeCount":95},[],{"trials":2880,"activeCount":95},[],{"trials":2882,"activeCount":95},[],{"trials":2884,"activeCount":95},[],{"trials":2886,"activeCount":95},[2887],{"nctId":2849,"briefTitle":2850,"status":103,"phases":2888,"primaryCompletion":1399,"completion":1399,"start":1376,"enrollment":2852,"conditions":2889,"interventions":2890},[87],[2854,2855],[2836,2857,2858,2859],{"trials":2892,"activeCount":95},[2893],{"nctId":2863,"briefTitle":2864,"status":103,"phases":2894,"primaryCompletion":2099,"completion":2099,"start":2866,"enrollment":283,"conditions":2895,"interventions":2896},[],[2868,2855,2869,2870],[2836,2857,2872,2858,2859,2873,2874],{"intervention":2858,"totalTrials":91,"cells":2898},{"EARLY_PHASE1":2899,"PHASE1":2901,"PHASE2":2903,"PHASE3":2905,"PHASE4":2907,"NA":2913},{"trials":2900,"activeCount":95},[],{"trials":2902,"activeCount":95},[],{"trials":2904,"activeCount":95},[],{"trials":2906,"activeCount":95},[],{"trials":2908,"activeCount":95},[2909],{"nctId":2849,"briefTitle":2850,"status":103,"phases":2910,"primaryCompletion":1399,"completion":1399,"start":1376,"enrollment":2852,"conditions":2911,"interventions":2912},[87],[2854,2855],[2836,2857,2858,2859],{"trials":2914,"activeCount":95},[2915],{"nctId":2863,"briefTitle":2864,"status":103,"phases":2916,"primaryCompletion":2099,"completion":2099,"start":2866,"enrollment":283,"conditions":2917,"interventions":2918},[],[2868,2855,2869,2870],[2836,2857,2872,2858,2859,2873,2874],{"intervention":2859,"totalTrials":91,"cells":2920},{"EARLY_PHASE1":2921,"PHASE1":2923,"PHASE2":2925,"PHASE3":2927,"PHASE4":2929,"NA":2935},{"trials":2922,"activeCount":95},[],{"trials":2924,"activeCount":95},[],{"trials":2926,"activeCount":95},[],{"trials":2928,"activeCount":95},[],{"trials":2930,"activeCount":95},[2931],{"nctId":2849,"briefTitle":2850,"status":103,"phases":2932,"primaryCompletion":1399,"completion":1399,"start":1376,"enrollment":2852,"conditions":2933,"interventions":2934},[87],[2854,2855],[2836,2857,2858,2859],{"trials":2936,"activeCount":95},[2937],{"nctId":2863,"briefTitle":2864,"status":103,"phases":2938,"primaryCompletion":2099,"completion":2099,"start":2866,"enrollment":283,"conditions":2939,"interventions":2940},[],[2868,2855,2869,2870],[2836,2857,2872,2858,2859,2873,2874],{"intervention":2824,"totalTrials":91,"cells":2942},{"EARLY_PHASE1":2943,"PHASE1":2945,"PHASE2":2947,"PHASE3":2949,"PHASE4":2951,"NA":2953},{"trials":2944,"activeCount":95},[],{"trials":2946,"activeCount":95},[],{"trials":2948,"activeCount":95},[],{"trials":2950,"activeCount":95},[],{"trials":2952,"activeCount":95},[],{"trials":2954,"activeCount":95},[2955,2959],{"nctId":2815,"briefTitle":2816,"status":103,"phases":2956,"primaryCompletion":2818,"completion":2818,"start":2819,"enrollment":2820,"conditions":2957,"interventions":2958},[],[2822],[1210,2824],{"nctId":2826,"briefTitle":2827,"status":103,"phases":2960,"primaryCompletion":2829,"completion":2829,"start":2830,"enrollment":2831,"conditions":2961,"interventions":2962},[],[2833],[1210,2824],{"intervention":2872,"totalTrials":127,"cells":2964},{"EARLY_PHASE1":2965,"PHASE1":2967,"PHASE2":2969,"PHASE3":2971,"PHASE4":2973,"NA":2975},{"trials":2966,"activeCount":95},[],{"trials":2968,"activeCount":95},[],{"trials":2970,"activeCount":95},[],{"trials":2972,"activeCount":95},[],{"trials":2974,"activeCount":95},[],{"trials":2976,"activeCount":95},[2977],{"nctId":2863,"briefTitle":2864,"status":103,"phases":2978,"primaryCompletion":2099,"completion":2099,"start":2866,"enrollment":283,"conditions":2979,"interventions":2980},[],[2868,2855,2869,2870],[2836,2857,2872,2858,2859,2873,2874],{"intervention":2873,"totalTrials":127,"cells":2982},{"EARLY_PHASE1":2983,"PHASE1":2985,"PHASE2":2987,"PHASE3":2989,"PHASE4":2991,"NA":2993},{"trials":2984,"activeCount":95},[],{"trials":2986,"activeCount":95},[],{"trials":2988,"activeCount":95},[],{"trials":2990,"activeCount":95},[],{"trials":2992,"activeCount":95},[],{"trials":2994,"activeCount":95},[2995],{"nctId":2863,"briefTitle":2864,"status":103,"phases":2996,"primaryCompletion":2099,"completion":2099,"start":2866,"enrollment":283,"conditions":2997,"interventions":2998},[],[2868,2855,2869,2870],[2836,2857,2872,2858,2859,2873,2874],{"intervention":2874,"totalTrials":127,"cells":3000},{"EARLY_PHASE1":3001,"PHASE1":3003,"PHASE2":3005,"PHASE3":3007,"PHASE4":3009,"NA":3011},{"trials":3002,"activeCount":95},[],{"trials":3004,"activeCount":95},[],{"trials":3006,"activeCount":95},[],{"trials":3008,"activeCount":95},[],{"trials":3010,"activeCount":95},[],{"trials":3012,"activeCount":95},[3013],{"nctId":2863,"briefTitle":2864,"status":103,"phases":3014,"primaryCompletion":2099,"completion":2099,"start":2866,"enrollment":283,"conditions":3015,"interventions":3016},[],[2868,2855,2869,2870],[2836,2857,2872,2858,2859,2873,2874],{"intervention":3018,"totalTrials":127,"cells":3019},"Ramipril, Irbesartan and Atorvastin",{"EARLY_PHASE1":3020,"PHASE1":3022,"PHASE2":3024,"PHASE3":3026,"PHASE4":3028,"NA":3030},{"trials":3021,"activeCount":95},[],{"trials":3023,"activeCount":95},[],{"trials":3025,"activeCount":95},[],{"trials":3027,"activeCount":95},[],{"trials":3029,"activeCount":95},[],{"trials":3031,"activeCount":95},[3032],{"nctId":3033,"briefTitle":3034,"status":3035,"phases":3036,"primaryCompletion":3037,"completion":3037,"start":3038,"enrollment":3039,"conditions":3040,"interventions":3041},"NCT02721342","Remission Clinic in Proteinuric Chronic Nephropathies","UNKNOWN",[],"2022-11","2009-06",1500,[2620],[3018],{"intervention":3043,"totalTrials":127,"cells":3044},"Mitomycin",{"EARLY_PHASE1":3045,"PHASE1":3047,"PHASE2":3049,"PHASE3":3051,"PHASE4":3053,"NA":3055},{"trials":3046,"activeCount":95},[],{"trials":3048,"activeCount":95},[],{"trials":3050,"activeCount":95},[],{"trials":3052,"activeCount":95},[],{"trials":3054,"activeCount":95},[],{"trials":3056,"activeCount":95},[3057],{"nctId":3058,"briefTitle":3059,"status":3035,"phases":3060,"primaryCompletion":3061,"completion":3061,"start":3062,"enrollment":3063,"conditions":3064,"interventions":3066},"NCT03914820","Prophylactic Surgery Plus HIPEC With CO2 in Patients Affected by Colorectal Carcinoma. CHECK Study.",[88],"2025-06-01","2020-06-19",330,[3065],"Colorectal Neoplasms",[3043],{"intervention":3068,"totalTrials":127,"cells":3069},"Oxycodone-Naloxone",{"EARLY_PHASE1":3070,"PHASE1":3072,"PHASE2":3074,"PHASE3":3076,"PHASE4":3078,"NA":3080},{"trials":3071,"activeCount":95},[],{"trials":3073,"activeCount":95},[],{"trials":3075,"activeCount":95},[],{"trials":3077,"activeCount":95},[],{"trials":3079,"activeCount":95},[],{"trials":3081,"activeCount":95},[3082],{"nctId":3083,"briefTitle":3084,"status":103,"phases":3085,"primaryCompletion":3086,"completion":3086,"start":3087,"enrollment":3088,"conditions":3089,"interventions":3091},"NCT02293785","GREAT - Good Response With Appropriate Treatment",[],"2016-02","2014-11",200,[2855,3090],"Neoplasms",[3068]]